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ABSTRACT 
PHOSPHOLIPASE C OF CLOSTRIDIUM HEMOLYTICUM: GENE 
CHARACTERIZATION AND PROOF OF ITS ROLE AS A PROTECTIVE 
IMMUNOGEN IN GUINEA PIGS 
Paul J. Hauer, D. V. M, M. S., and Ricardo F. Rosenbusch, D. V M, Ph D 
The phospholipase C (PLPC) gene from Clostridium hemolyticum was cloned using the 
polymerase chain reaction. An open reading frame which encodes a 399-amino acid protein, 
containing a 27-amino acid signal sequence, was identified. The molecular weight of the 
active protein was 42,869 daltons. A 16-amino acid N-terminal sequence determined by 
Edman degradation exactly matched the putative amino acid sequence of the gene product. 
Comparison of the nucleotide and amino acid sequences with Genbank databases 
demonstrated that the beta toxin of C. hemolyticum exhibits high homology with other 
bacterial PLPCs. The N-terminal portion of the beta toxin contains the zinc-binding domain 
common to other bacterial PLPCs, and the C-terminal domain of the beta toxin protein shows 
considerable homology with the C-terminal domains of C. perfringens alpha toxin and 
C. novyi type A PLPC, and the N-terminal domain of bovine arachidonate 5-lipoxygenase. 
The beta toxin of C. hemolyticum was purified by preparative isoelectric focusing and used 
1 Center for Veterinary Biologies, Licensing and Policy Development, United States 
Department of Agriculture, Ames, Iowa 50010 
2 Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa 
State University, Ames, Iowa 50010 
vi 
to develop toxin neutralizing and non-neutralizing monoclonal antibodies. Guinea pigs 
passively immunized with toxin-neutralizing monoclonal antibodies were protected from a 100 
LDso spore challenge. The toxin-neutralizing ability of the monoclonal antibodies, as 
measured in in vitro and in vivo toxin neutralization assays, correlated to the protective effects 
in guinea pigs. Protection of guinea pigs injected with varying doses of immunoaffinity 
purified beta toxin was correlated to the presence of anti-beta toxin antibodies in the serum. 
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CHAPTER 1. GENERAL INTRODUCTION 
Introduction 
Clostridium hemolyticum is a species of anaerobic, spore-forming bacteria that is the 
etiologic agent of a fatal disease in cattle and sheep known as bacillary hemoglobinuria. The 
pathogenesis of the disease is attributed mainly to the action of a potent, toxic 
phospholipase C (PLPC) produced by the organism. Despite sporadic occurrences of this 
disease and the common use of preventative vaccination in many parts of the world, little has 
been done to improve the diagnosis or prevention of this disease since the first vaccines were 
developed over seven decades ago. 
Vaccines containing C. hemolyticum that are currently licensed in the United States are 
tested for potency using a guinea pig challenge test. This test causes pain and suffering in a 
large number of animals each year and has been targeted by regulatory officials as a test that 
needs to be replaced. In order to develop a suitable alternative in vitro antigen quantitation 
test, protective immunogens of C. hemolyticum need to be identified. 
Recent studies of PLPCs produced by bacteria closely related to C. hemolyticum have 
resulted in improved diagnostic techniques, a new generation of vaccines, and key insights 
into the contribution of PLPCs to disease pathogenesis and their possible role as protective 
immunogens. The goals of the research contained in this dissertation were 1) to determine the 
genetic sequence of the PLPC of C. hemolyticum, and 2) to determine the role of the toxin as 
a possible protective immunogen using a guinea pig challenge model. Hopefully this research 
will serve as a foundation on which better diagnostic techniques, better vaccines, and a more 
humane vaccine potency test will be developed. 
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Dissertation Organization 
This dissertation consists of two scientific studies addressing the two specific goals of the 
research. The scientific studies are preceded by a literature review and followed by a general 
summary. References cited in the literature review are listed immediately following. The 
studies presented in papers I and II will be submitted for publication in Anaerobe and Vaccine, 
respectively. Appendix I contains preliminary results from work on the development of a 
multiplex polymerase chain reaction (PCR) for identifying C. novyi types A and B, and C. 
hemolyticum based on amplification of segments of their alpha and beta toxin genes. The 
study was designed to be published in The Journal of Veterinary Diagnostic Investigation as 
a brief communication when completed. Appendix n contains the PCR parameters used to 
amplify the C. hemolyticum beta toxin gene for insertion into an expression plasmid cut with 
the endonuclease Hind HI. 
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CHAPTER 2. LITERATURE REVIEW 
Clostridium hemolyticum 
Clostridium hemolyticum is an anaerobic bacterium capable of producing a rapidly fatal 
disease in cattle and sheep known as "bacillary hemoglobinuria" or "redwater". The 
bacterium, initially named Clostridium hemolyticus bovis, was first described by Vawter and 
Records' in 1926 as the causative agent of a disease that had been endemic in certain valleys 
along the eastern base of the Sierra Nevada mountains in Nevada, California, and Southern 
Oregon23. Initially the disease was thought to be restricted to these areas west of the Rocky 
Mountains. However, subsequent reports indicated the disease presence in the southern, 
midwestem, and western United States as well as numerous other countries including: Wales, 
New Zealand, Canada, Australia, Romania, Turkey, Cuba, the West Indies, Mexico, 
Venezuela, Chile, Brazil, Iran, Ireland, and India4"18. 
Clostridium hemolyticum is a large Gram positive sporulating bacillus. Like some other 
clostridial organisms, it looses the ability to retain stain and therefore may appear Gram 
negative in cultures over 24 hours old. The bacterium is 3-5 |i.m long and approximately 1 pirn 
wide. Cells contain numerous peritrichous flagella, which impart motility, and oval, 
subterminal spores. The spores are relatively resistant to killing and are able to survive boiling 
for 30 minutes, as well as extended exposure to many common disinfectants, including phenol 
and quaternary ammonium compounds. The organism is extremely fastidious and is rated as 
one of the strictest anaerobes known19-20. 
Strains of C hemolyticum demonstrate remarkable uniformity in regard to their 
biochemical and serological characteristics21. Clostridium hemolyticum is closely related to 
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C. novyi (previously C. oedematiens) type B, which causes a disease known as "black 
disease" with a somewhat similar pathogenesis to bacillary hemoglobinuria22. The similarities 
in cultural characteristics and protein electrophoresis patterns23, as well as DNA homology24 
between the 2 organisms are extensive. The main difference between C. novyi type B and 
C. hemolyticum is the production of alpha toxin by C. novyi type B organisms25. Alpha toxin 
is a protein of approximately 250 kDa which is lethal to mice. Its catalytic action inactivates 
proteins from the Ho family that regulate actin polymerization in eukaryotic cells26. 
Researchers have demonstrated conversion of C. hemolyticum to C. novyi type B and vice 
versa by infection with, or curing of, a phage which carries the alpha toxin gene21. Because of 
the extensive homology between the 2 organisms, some researchers consider C. hemolyticum 
to be included within the G novyi species and refer to it as C. novyi type D2*. 
Pathogenesis of Bacillary Hemoglobinuria 
Bacillary hemoglobinuria is a sporadic disease that is infectious, but not contagious. 
Evidence suggests that the spread of the disease may be due to movement of asymptomatic 
carrier cattle from an infected region29. Although primarily a disease of cattle, bacillary 
hemoglobinuria has been reported in sheep, hogs, horses, buffalo, and elk11-30"33. In areas 
where the disease is endemic, spores are ingested or inhaled in contaminated feed, water, or 
dust. The spores are absorbed and transported in the blood to the liver, where they remain 
latent until an anaerobic environment is established. The disease manifests itself after some 
predisposing factor induces an insult to the liver which produces a necrotic area with an 
anaerobic environment in which the bacterial spores are able to germinate. Vegetative cells 
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grow and exude toxins, resulting in more tissue destruction and eventually clinical disease and 
death. The incubation period is generally accepted to be a minimum of 5 days. Typically the 
incidence of the disease is under 2 percent in infected herds, but the case fatality rate 
approaches 100 percent. Death losses up to 25 percent have been reported in naive cattle 
herds moved on to infected pastures34. 
Various factors can damage the liver and precipitate disease, including migration of liver 
flukes (Fasciola hepatica), severe liver congestion, exposure to intoxicants19, invasion by 
tapeworms (Cysticercus tenuicollis)11, or Fusobacterium necrophorum infection secondary to 
ruminitis9. The disease is found more commonly in irrigated and poorly drained pastures in 
areas endemic for liver flukes, suggesting that flukes are a predominant predisposing factor; 
however, the disease also is seen in areas where fascioliasis rarely occurs. 
The theory that anaerobic conditions established in damaged tissue allow dormant spores 
to germinate, proliferate, and exude toxins has recently been confirmed by studies 
demonstrating the preferential colonization of tumors by Clostridia species where spores 
germinate only in the anaerobic, necrotic environment of the tumors and not in healthy 
tissue35. Additional evidence to verify the pathogenesis comes from that fact that 
C. hemolyticum has been isolated from the liver and kidneys of apparently healthy cattle36. 
Like other species of the genus Clostridia, most, if not all, of the pathogenicity of 
C. hemolyticum is attributed to the production of biologically active exotoxins. The main 
toxin of C. hemolyticum is a phospholipase C, known as beta toxin28. The beta toxin lyses 
hepatocytes and erythrocytes and damages capillary endothelium which leads to 
hemoglobinuria and loss of vascular fluids into tissues and serous cavities. Death usually 
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occurs within 24-36 hours of the onset of clinical disease and is believed to be caused from 
anoxia resulting from the destruction of erythrocytes. Common post-mortem findings include 
liver infarcts, hemorrhagic small intestines, and port wine-colored fluid in the bladder. 
Hemoglobinuria is first observed when 30-50% of the red blood cells have been hemolyzed, 
and over 75% of the erythrocytes may be lysed at the time of death19. Hemoglobinuria may 
be absent many times in animals with incomplete immunity37. In such cases, the animals die 
about a week after showing disease symptoms, with liver lesions being a consistent 
post-mortem finding. 
Clostridium hemolyticum can be recovered from the liver, spleen, heart blood, and other 
organs of cattle that have died of bacillary hemoglobinuria. The infection frequently becomes 
bacteremic before death. The organism is excreted in the feces and urine of asymtomatic 
carrier animals, as well as clinically affected animals. Viable C. hemolyticum spores have been 
isolated from the bone marrow cavities of cattle up to a year after the animals died of the 
disease38, and decomposing carcasses of animals killed by C. hemolyticum are a potent source 
of infection. 
The disease has been reproduced in cattle, sheep, and rabbits by oral or intravenous 
inoculation of C. hemolyticum spores, followed by liver biopsy. It also has been reproduced 
by inoculating spores and 40% calcium chloride directly into the livers of cattle39-41. 
However, researchers were unable to reproduce the disease by repeated oral administration of 
Fasciola hepatica metacercariae and C. hemolyticum spores in cattle and rabbits4. During 
experimental reproduction of the disease in rabbits, latent spores were demonstrated by 
immunoflourescent staining to localize within Kupffer's cells 42. 
I 
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Diagnosis of Bacillary Hemoglobinuria 
Clinical diagnosis of bacillary hemoglobinuria is normally based on characteristic clinical 
signs and post-mortem findings. Laboratory confirmation of the diagnosis is ideally based on 
cultivation of C. hemolyticum, but the fastidious nature of the organism and contamination by 
other post mortem invading bacteria make the task difficult43. Immunohistochemical 
methods, such as immunofluorescence and immunoperoxidase staining methods, are used 
many times in place of culture "4. A diagnosis of bacillary hemoglobinuria in the absence of 
culture results should be made keeping in mind the following criteria: 1) clinical history, 2) 
post mortem findings, 3) relative numbers of clostridial organisms per microscopic field on 
stained tissue or impression smears, 4) the time that has elapsed between death of the animal 
and the taking of the samples, bearing in mind the ambient temperature45. 
Correct identification of C. hemolyticum is complicated by the difficulty in differentiating it 
from other very closely related C. novyi species. Commercially available fluorescent antibody 
conjugates do not differentiate the species, and differentiation is done mainly by demonstrating 
the presence and specific neutralization of 2 toxins, alpha and beta, both of which are lethal 
when injected into mice. Clostridium novyi type A produces alpha toxin, but not beta toxin; 
C. novyi type B produces both toxins; C. novyi type C produces neither toxin; and 
C. hemolyticum produces only beta toxin. In vitro methods used to demonstrate the presence 
of alpha and beta toxins such as cell culture assay, hemolytic activity, or reactivity on egg 
yolk agar are complicated by the presence of non-lethal phospholipases C and lipases 
produced by C. novyi and C. hemolyticum 25. Improvement in diagnostic tests and methods of 
differentiation of the closely related organisms is warranted. 
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Vaccination Against Bacillary Hemo^obinuria 
Prior to the establishment of the correct etiology of bacillary hemoglobinuria, many cattle 
deaths were incorrectly attributed to anthrax, which unjustly cast doubt on the effectiveness of 
anthrax vaccines4. Successful vaccination against bacillary hemoglobinuria with inactivated 
whole culture, as well as with whole culture of live avirulent bacteria, was first reported by 
Vawter and Records in 1929*. In the inactivated vaccine study, toxoid was presumed to 
provide the protective immunity, and formalin treatment was shown to destroy the ability of a 
vaccine to induce protective immunity. Immunity from live avirulent bacteria lasted longer 
than immunity induced by inactivated whole culture. However, widespread use of the live 
avirulent vaccine was hindered because of the danger involved with using live organisms and 
also because of the common large (<10 cm) localized injection site reactions appearing 
approximately six hours post-vaccination, possibly due to the presence of active toxin4. 
The literature is unclear as to the relative contribution of C. hemolyticum toxoid vs. 
cellular components in inducing a protective immune response. In 1945 Records and Vawter 
reported that intravenous administration of hyperimmune horse serum containing high levels 
of antitoxin was an effective treatment if administered early in the course of the disease, 
while administration of a hyperimmune horse serum containing high agglutination titers was of 
no use, which suggests the importance of toxoid in inducing protective immunity 4 The 
relatively short duration of the immunity (approximately 6 months) induced by early 
inactivated vaccines was attributed to the fact that the beta toxin, like other phosopholipases 
C, was poorly antigenic47. Refined toxoiding techniques led to toxoids that were capable of 
inducing relatively high antitoxin titers in cattle; however, no challenges were conducted to 
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evaluate the protective immunity induced by these new toxoids48-49. Claus attempted to 
increase the duration of immunity induced by vaccination by using a formalin-inactivated 
washed whole cell preparation with a mineral oil adjuvantso. Cattle vaccinated with the 
oil-adjuvanted vaccine had significant agglutination titers 577 days post-vaccination. Claus 
established a correlation between agglutination titers and protection against a lethal challenge 
in guinea pigs and concluded that immunity was primarily antibacterial in nature. However, 
the correlation between agglutination titers and protection in cattle was not evaluated. Smith 
reported the presence of antigens shared between C. hemolyticum and other "variant" 
organisms that induced agglutination titers and cautioned against the use of serological tests 
to identify infected or immune cattle51. As a result of the contradictory evidence in the 
literature, modern textbooks address the topic with cautious statements, such as: "It has been 
suggested, but not confirmed that immunity (to bacillary hemoglobinuria) is primarily 
antibacterial,"52 or "The immunity is apparently antibacterial rather than antitoxic in nature, 
although the situation is far from clear"19. 
Commercial vaccines currently available are formalin-killed whole cultures that consistently 
induce agglutinating antibodies, but only occasionally induce measurable antitoxin titers l9. 
Few, if any, major improvements in the vaccine formulations have been accomplished despite 
their widespread use, in the 6 decades since the inception of the prototypes. Vaccination of 
cattle, especially in fluke infested areas, is commonly practiced, though the duration of 
immunity remains relatively short lived and revaccination at 6-month intervals is normally 
recommended. Continual revaccination tends to decrease incidence in infected areas; 
however, complete eradication of the disease is never accomplished53. 
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Most C. hemolyticum-œntaimng vaccines currently licensed in the United States are 
marketed as combination vaccines which contain antigens from several pathogenic species of 
Clostridia. Prior to licensure, the vaccines must be proven efficacious in cattle. Cattle 
challenge studies are conducted by administering virulent spores, diluted in a calcium chloride 
solution, intrahepatically to both vaccinated and non-vaccinated control animals. After 
licensure, the quality of each batch of vaccine is monitored using a guinea pig 
vaccination/challenge test codified in the Code of Federal Regulations54. Vaccinated and 
non-vaccinated guinea pigs are challenged intramuscularly with 100 guinea pig LD* of a 
standardized spore suspension diluted in a calcium chloride solution55. Both the cattle and 
guinea pig challenge models result in significant amounts of pain, suffering, and mortality in 
non-immune animals. 
Clostridium hemolyticum Beta toxin 
Records and Vawter (1945) reported that C. hemolyticum produces 2 toxic fractions in 
culture supernatant, one highly hemolytic and unstable, disappearing after 36 hours of 
incubation, and one necrotizing fraction which persists for a week or more at 37°C. The 
hemolytic toxin, named beta toxin, was determined to be the most significant factor in the 
production of disease 4. In subsequent experiments, Jasmin demonstrated that the hemolytic 
and necrotizing characteristics of culture supernatant were attributable to a single substance 56 
Beta toxin is a calcium-dependent enzyme that cleaves the phospholipid lecithin 
(phosphatidylcholine) by hydrolysis into phosphocholine and a diglyceride57. Such enzymatic 
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action classifies the beta toxin as a lecithinase or, using a more general name, a phospholipase 
C (PLPC). Serologically, the beta toxin of C. hemolyticum is identical to the beta toxin of 
C. novyi type B, but distinct from the PLPCs of C. novyi type A, C. perfiringens type A, and 
C. bifermentans58. 
Other than establishing its catalytic identity, very little has been done to characterize the 
beta toxin of C. hemolyticum. In a single study, Darakhshan and Lauerman59 used 2 different 
culture techniques and 6 different media in an effort to optimize beta toxin production. They 
found that toxin production peaked at 18 hours of incubation at 37°C and was highest using a 
mixture of trypticase peptone, proteose peptone, yeast extract, glucose, and sodium 
thioglycollate. The same researchers partially purified the toxin and reported it was stable at 
50°C for 60 minutes and rapidly inactivated by trypsin. The molecular weight of beta toxin 
was estimated to be 32,000 daltons as determined by sodium dodecyl sulfate polyacrylamide 
gel electorphoresis. 
Bacterial Phospholipases C and Their Role in Virulence 
Phospholipases are enzymes that cleave the phosophodiester linkage between the 
phosphate-containing polar head and hydrophobic lipid tails of phospholipid molecules. The 
enzymes, whose function in bacteria is believed to be to secure stores of phosphate required 
for growth, have been isolated from a variety of Gram positive and Gram negative organisms. 
Phospholipases C are distinguished from phospholipases A and B by the site at which they 
cleave phospholipids (Fig 1)60 Phospholipases C have been classified into 3 groups: those 
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that degrade phosphatidylcholine (lecithin), those that degrade sphingomyelin, and those that 
degrade phosphatidylinositol (Fig 2)61. 
Nonpolar tails Polar head group 
Fatty acid 
Serine Choline PO 
Fatty acid 
PLC 
PLD 
Figure 1. Sites of phospholipid hydrolysis by phospholipases A2, C, and D. While the 
specific head and tail groups may differ, the cleavage site relative to the phosphate moiety 
remains constant. 
The first bacterial PLPC was reported by MacFarlane and Knight62 in 1941 in a landmark 
study that identified the biochemical basis of disease caused by the catalytic action of the alpha 
toxin of Clostridium perfiringens. A limited amount of new information about bacterial 
PLPCs was discovered between the time of that initial breakthrough and the 1980s, when the 
cloning and DNA sequencing of PLPC genes ushered in a surge in research. Several 
bacterial PLPC genes have been cloned and sequenced including those from Pseudomonas 
aeruginosa63, P. cepacia 64, Bacillus thuringiensis6S, B. cereus66, Clostridium 
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bifermentans61, C. perfiringens 64 69, C. novyi type A70, Listeria monocytogenes71 •72, 
Staphylococcus aureus73, and Aeromonas hydrophilia 74. DNA and protein sequence 
comparisons reveal the presence of a highly conserved domain throughout the PLPCs from 
phosphatidylcholine 
R-I— C— O —|CH2 
T°T $ 
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OH 
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O 
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R,_ c- O ~ C!H 9 
& ck 
O 
I 
c=o 
I + 
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o 
Figure 2. Structure of major phospholipids. Cleavage site by phospholipase C is indicated 
with and arrow. 
the Gram positive bacteria. All consist of a single polypeptide chain that contain essentially 
placed amino acids necessary for the coordinated binding of zinc ions, which are required for 
enzymatic function75. Most of the homology is located in the 250 N-terminal amino acids61. 
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Potential mechanisms by which PLPCs contribute to virulence in bacterial disease have 
been proposed, and some have begun to be verified®. The toxic properties of the PLPCs 
may be due to their ability to directly damage cell membranes by cleaving phospholipids, or by 
the indirect effects of their actions on. cell signaling pathways. Increased diacylyglycerol and 
ceramide, caused by PLPC action on phosophatidylcholine and sphingomyelin, respectively, 
activate protein kinases C in cell membranes. These in turn activate eukaryotic 
phospholipases, leading to formation of inositol 1,4,5 triphosphate and inositol 1,3,4,5 
tetraphosphate. Uncontrolled production of these molecules effectively deregulates cellular 
calcium, which contributes to the deregulation of several cellular processes76. Bacterial 
PLPCs also activate the arachidonic acid cascade in eukaryotic cells, resulting in the 
production of thromboxane and prostaglandin, which, if uncontrolled, can contribute to 
pathogenesis of disease. In addition, bacterial PLPCs that are able to degrade 
phosphatidylinositol can cleave glycosylphosphatidylinositol (GPI)-anchored proteins from the 
surface of eukaryotic cells, thereby disrupting a myriad of cell signaling pathways 77 
Clues to the specific roles that PLPCs play in bacterial virulence have been demonstrated 
in various experiments. The most toxic of the PLPCs characterized is the alpha toxin of 
C. perfiringens which possesses potent hemolytic, lethal, dermonecrotic, myonecrotic, 
vascular permeabilizing, and platelet-aggregating properties. Interestingly, the C-terminal 
domain of C. perfringens alpha toxin, which is thought to confer its hemolytic and lethal 
properties, has sequence homology with an enzyme from the human arachidonic acid pathway 
involved in the generation of leukotrienes78. Intradermal administration of alpha toxin in 
guinea pigs activates lipoxygenase and cyclooxygenase pathways, yielding thoromboxanes, 
15 
leukotrienes, and prostaglandins. Researchers have recently demonstrated that alpha toxin 
activates the platelet fibrinogen receptor gpllbllla, which results in the binding of free 
fibrinogen to platelets and formation of platelet/granulocyte complexes resulting in sustained 
thrombosis, vascular injury, and muscle destruction79. 
The mechanism by which 2 related PLPCs from the intracellular bacterial pathogen 
Listeria monocytogenes contribute to virulence has also been demonstrated. The PLPCs play 
a critical role in allowing the bacteria to escape from phagolysosomes and to escape 
double-membraned vesicles formed as a result of cell-to-cell spread of the bacteria. A mutant 
L. monocytogenes deficient in both PLPCs was 500-fold less virulent than the wild type in 
mice80. 
Using similar genetic techniques, Merino, et. al.74 showed that Aeromonas hydrophilia 
mutants lacking PLPC were 10-fold less virulent in fish than the same mutants complemented 
with the PLPC gene. In yet another example of the virulence of PLPC, the disease in sheep 
known as "fleecerot", caused by Pseudomonas aeruginosa, can be reproduced by intradermal 
inoculation of the purified PLPC 71. 
Potential Applications of Bacterial Phospholipases C 
The intense interest in bacterial PLPCs over the past decade is due, in part, to their 
potential application in therapeutics and research. Recombinant C. perfringens alpha toxin 
has been used successfully as a vaccine against gas gangrene ", and other recombinant 
bacterial PLPCs including that of C. hemolyticum, may represent promising vaccine 
candidates. Attempts to produce an immunotoxin which could impart cytotoxic effects from 
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the exterior of a target cell by conjugation of C. perfringens alpha toxin have thus far yielded 
mixed results83-84, but if successful may improve upon immunotoxins evaluated thus far made 
with diphtheria toxin, ricin, or Pseudomonas exotoxin A, all of which must be internalized to 
be active. Similarities in structure to eukaryotic PLPCs and the advantage of relatively large 
available quantities may make bacterial PLPCs useful as models for studying their eukaryotic 
counterparts61 and may lead to low cost methods for design of drugs affecting the numerous 
biochemical pathways influenced by PLPCs. 
Literature Cited 
1. Vawter, L. R. and Records, E. 1926. Recent studies on ictero-hemoglobinuria of cattle. 
J. Am. Vet. Med. Assoc. 68: 494-513. 
2. Meyer, K. F. 1916. Studies to diagnose a fatal disease of cattle in the mountainous 
regions of California. J. Am. Vet. Med. Assoc. 48: 552-565. 
3. Mack, W. B. and Records, E. 1917. Studies of an obscure cattle disease in western 
Nevada. J. Am Vet. Med. Assoc. 52: 143-151. 
4. Records, E. and Vawter, L. R. 1945. Bacillary hemoglobinuria of cattle and sheep (Red 
Water Disease). Technical Bulletin published by the University of Nevada, Reno, 
Nevada. 
5. Rastas, V. P., Myers, G. H, and Lesar, S. 1974. Bacillary hemoglobinuria in Wisconsin 
cattle. J. Amer. Vet. Med. Assoc. 12: 1203-1204 
6. Williams, B M 1964. Clostridium oedematiens infections (Black disease and bacillary 
haemoglobinuria) of cattle in mid-Wales. Vet. Rec. 76: 591-596. 
17 
7. Marshall, S. C. 1959. The isolation of Clostridium hemolyticum from cattle in New 
Zealand. New Zealand Vet. J. 7: 115-119. 
8. Quinlivan, T D and Wedderburn, J. F. 1959. Bacillaiy haemoglobinuria in cattle in New 
Zealand. New Zealand Vet. J. 7: 113-115 
9. Janzen, E., Orr, J. P., and Osborne, A. D. 1981. Bacillary hemoglobinuria associated 
with hepatic necrobacillosis in a yearling feedlot heifer. Can. Vet. J. 22: 393-394. 
10. Wellington, N. A. M and Perceval, A 1966. Bovine bacillary haemoglobinuria in 
Victoria. Australian Vet. J. 42: 128-130. 
11. Hreczko, I. 1959. Infectious necrotic hepatitis in sheep in south Australia, possibly 
associated with Cysticercus tenuicollis. Aust. Vet. J. 35: 462-465. 
12. Williams, H. E. 1973. Clostridium oedematiens infection in cattle in Trinidad, West 
Indies. Vet. Record. 92: 451-452. 
13. Andersen, E. H. 1950. Bacillary hemoglobinuria (red water disease) in Chile. Nord. 
Vet. Med. 2:688-696. 
14. Seifert, H. S. H, Bader, K. M., Cyplik, J., Gonzalez-Salinas, J., Roth, F , Salinas-
Melendez, A., and Sukop, U. 1996. Environment, incidence, aetiology, epizoology and 
immunoprophylaxis of soil-borne diseases in north-east Mexico. J. Vet. Med. B 43: 
593-606. 
15. Peron, E. and Garcia, J. C. 1980. Epizootic behavior of bovine bacillary 
icterohemoglobinuria (BBI) hemoglobinuria, jaundice in Cuba. Rev. Cub Cienc. Vet. 
11: 13-20. 
18 
16. Ardehali, M. and Darakhshan, H 1977. First report of infection with Clostridium 
oedematiens type D in sheep in Iran. Arch. Inst. Razi. 29: 91-93. 
17. Power, E. P., White, V. J., Mackessy, E. J., and Ward, J. 1987. Bacillary 
haemoglobinuria in cattle: confirmation of the disease in Ireland. Irish Vet. J. 41: 
255-257. 
18. Randhawa, S. S., Sharma, D K , Randhawa, C. S., Gill, B. S., Brar, R. S., and Singh, J. 
1995. An outbreak of bacillary haemoglobinuria in sheep in India. Trop. Animal Health 
and Prod. 1: 31-36. 
19. Smith, L. D, 1975. Clostridium haemolyticum. In A. Balows, ed. The Pathogenic 
Anaerobic Bacteria, Pp. 271-280. Charles C. Thomas, Springfield. 
20. Hatheway, C. L. 1990. Toxigenic Clostridia. Clin. Microbiol. Rev. 3: 66-98. 
21. Vawter, L. R. and Records, E. 1931. Serologic study of sixteen strains of Bacillus 
hemolyticum. J. Infect. Dis. 48: 581-587. 
22. Erwin, B. G. 1978. Clostridial hepatitis in cattle (Black disease and bacillary 
hemoglobinuria). Proc. U. S. An. Health Asscoc. 82: 61-67. 
23. Poxton, I. R. 1984. Demonstration of the common antigens of Clostridium botulinum, 
C. sporogenes, and C. novyi by an enzyme-linked immunosorbent assay and electroblot 
transfer. J. Gen. Microbiol. 130: 975-981. 
24. Nakamura, S., Kimura, I., Yamakawa, K., and Nishida, S. 1983. Taxonomic 
relationships among Clostridium novyi types A and B, Clostridium hemolyticum and 
Clostridium botulinum type C. J. Gen. Microbiol. 129: 1473-1479. 
19 
25. Rutter, J. M. and Collee, J. G. 1969. Studies on the soluble antigens of Clostridium 
oedematiens (Cl. novyi). J. Med. Microbiol. 2: 395-417. 
26. Selzer, J., Hofinann, F, Rex, G , Wilm, M , Mann, M., Just, I., and Aktories, K. 1996. 
Clostridium novyi alpha-toxin-catalyzed incorporation of GlcNAc into the Ho subfamily 
proteins. J. Biol. Chem. 271: 25173-25177. 
27. Eklund, M. W, Poysky, F. T., Peterson, M E, and Meyers, J. A. 1976. Relationship of 
bacteriophages to alpha toxin production in Clostridium novyi types A and B. Infect. 
Immunol. 14: 793-803. 
28. Oakley, C. L. and Warrack, G. H. 1959. The soluble antigens of Clostridium 
oedematiens type D (Cl. haemolyticum). J. Path. Bact 78: 543-551. 
29. S afford, J. W. and Smith, L. D. S. 1954. Epizootiology of bacillary hemoglobinuria. 
Proc. Am. Vet. Med. Assoc. 91: 159-162. 
30. Records, E. and Huber, M 1931. Bacillus hemolyticum infection in a hog. J. Am. Vet. 
Med. Assoc. 78: 863-865. 
31. Oaks, J. L., Kanaly, T. S., Fisher, T. J., and Besser, T E 1997. Apparent Clostridium 
hemolyticum /Clostridium novyi infection and exotoxemia in two horses. J. Vet. Diag. 
Invest. 9: 324-325. 
32. Mahato, S. N., Harrison, L. J. S., and Hammond, J. A. 1995. Bacillary haemoglobinuria 
in a buffalo calf: a case report. Vet. Rev. Kathmadu. 9-10: 36-37. 
33. Bender, L. C , Hall, P. B , Garner, M M., and Oaks, J. L. 1999. Bacillary 
hemoglobinuria in a free-ranging elk calf. J. Zoo Wildl. Med. 30: 293-296 
34. Stogdale, L. and Booth, A. J. 1984. Bacillary hemoglobinuria in cattle (Clostridium 
novyi type D infection.). Comp. Cont. Educ. Pract. Vet. 6: S284-S290. 
35. Lemmon, M.J., van Zijl, P., Fox, M.E., Mauchline, M.L., Giaccia, A.J., Minton, N.P., 
and Brown, J. M. 1997. Anaerobic bacteria as a gene delivery system that is controlled 
by the tumor microenvironment. Gene Ther. 4: 791-796. 
36. Smith, L. D. S. and Jasmin, A M. 1956. The recovery of Clostridium hemolyticum 
from livers and kidneys of apparently normal cattle. J. Am. Vet. Med. Assoc. 129: 68-71. 
37. Smith, L. D. S. 1956. The control of bacillary hemoglobinuria. Proc. U.S. Livestock 
San. Assoc. 60: 135-138. 
38. Jasmin, A. M. 1947. Isolation of Clostridium hemolyticum from bones. Am. J Vet. 
Res 8: 341-342. 
39. Olander, H. J, Hughes, J. P., and Biberstein, E L 1966. Bacillary hemoglobinuria: 
Induction by liver biopsy in naturally and experimentally infected animals. Path. Vet 3 : 
421-450. 
40. Erwin, B 1977. Experimental induction of bacillary hemoglobinuria in cattle. Am. J. 
Vet. Res 38: 1625-1627. 
41. Van Kampen, K. R. and Kennedy, P. C. 1969. Experimental bacillary hemoglobinuria. 
Path. Vet. 6: 59-75. 
42. Van Kampen, K. R. and Kennedy, P. C. 1968. Experimental bacillary hemoglobinuria. 
Intrahepatic detection of spores of Clostridium hemolyticum by immunofluorescence in 
the rabbit. Am. J. Vet. Res. 11: 2173-2177. 
21 
43. Colle, J. G , Rutter, J.M., and Watt, B. 1971. The significantly viable particle: A study 
of the subculture of an exacting sporing anaerobe. J. Med. Microbiol 4: 271-288. 
44. Uzal, F A, Belak, K., Rivera, E, Robles, C. A., and Feinstein, R E. 1992. Bacillary 
haemoglobinuria diagnosis by the peroxidase-antiperoxidase (PAP) technique. J. Vet. 
Med. B. 39: 595-598. 
45. Batty, I. and Walker, P. D. 1967. The incidence of Clostridium oedematiens in 
post-mortem material. Vet. Record. 80: 32. 
46. Vawter, L. R. and Records, E. 1929. Immunization of cattle against bacillary 
hemoglobinuria. J. Am. Vet. Med. Assoc. 75 . 201-204. 
47. Claus, K.D. and Macheak, M E 1965. Nonantigenic nature of Clostridium 
hemolyticum toxoid. Am. J. Vet. Res. Ill: 353-356. 
48. Lozano, E. A. 1977. Inactivation of Clostridium hemolyticum toxic fluids and their 
antigenicity. Can. J. Comp. Med. 41: 188-194. 
49. Lozano, E. A 1981. Antigenicity of bacillary hemoglobinuria toxoids in cattle. Am. J. 
Vet. Res. 42: 1641-1644. 
50. Claus, K. 1964. A mineral oil adjuvant vaccine for bacillary hemoglobinuria. Am. J. 
Vet. Res. 25:699-703. 
51. Smith, L. D. S., Claus, C. D , and Matsuoka, T 1956. A maltose-fermenting variant of 
Clostridium hemolyticum. J. Bacterid. 72. 809-812. 
52. Songer, J. G. 1997. Clostridial diseases of animals. In The Clostridia: Molecular 
Biology and Pathogenesis. P. 166. University Press, Cambridge. 
22 
53. Hjerpe, C. A 1990. Clostridial disease vaccines. In Veterinary Clinics of North 
America Food Animal Practice. Pp 228-229. 
54. Anonymous. 2001. In Code of Federal Regulations, Animals and Animal Products, 
Title 9, Part 113, Section 107. 2001. National Archives and Records Administration, 
Washington, D. C. 
55. Kolbe, D. R, Claus, K. D, and Nervig, R M 1981. A method for the production of 
Clostridium hemolyticum spores on solid medium. J. Biol. Stand. 9: 115-119. 
56. Jasmin, A M. 1947. Enzyme activity in Clostridium hemolyticum toxin. Am. J Vet. 
Res. 8: 289-293. 
57. MacFarlane, M G. 1950. The biochemistry of bacterial toxins: the lethicinase activity 
of Clostridium hemolyticum toxin. Biochem. J 47: 267-270. 
58. Oakley, C. L., Warrack, G. H, and Clark, P. H. 1947. The toxins of Clostridium 
oedematiens (CI. novyi). J. Gen. Microbiol. 1: 91-107. 
59. Darakhshan, H. and Lauerman, L. H. 1981. Some properties of beta toxin produced by 
Clostridium hemolyticum strain IRP-135. Comp. Microbiol. Immunol. Infect. Dis. 4: 
307-316. 
60. Songer, J.G. 1997. Bacterial phospholipases and their role in virulence. Trends 
Microbiol. 5: 156-161. 
61. Titball, R. W. 1993. Bacterial phospholipases C. Microbiol. Rev. 57: 3487-366 
62. MacFarlane, M G and Knight, B. C. 1941. The biochemistry of bacterial toxins. I. 
Lecithinase activity of Clostridium welchii toxins. Biochem. J. 35. 884-902. 
23 
63. Coleman, K., Dougan, G., and Arbuthnott, J. P. 1983. Cloning and expression in 
Escherichia coli K12 of the chromosomal hemolysin (phospholipase C) determinant of 
Pseudomonas aeruginosa. J. Bacteriol. 153: 909-915. 
64. Vasil, M. L, Kreig, J. S., Kuhns, J. S., Ogle, J. W, Shortridge, V D, Ostroff, R. M. and 
Vasil, A I 1990. Molecular analysis of haemolytic and phospholipase C activities of 
Pseudomonas cepacia. Infect. Immun. 58: 4020-4029. 
65. Henner, D. J, Yang, M., Chen, E., Hellmiss, R, Rodriguez, H, and Low, M G 1988. 
Sequence of the Bacillus thuringiensis phosphatidylinositol specific phospholipase C. 
Nucleic Acid Res. 16:10383-10391. 
66. Kuppe, A., Evans, L.M., McMillen, D A , and Griffith, O H 1989. 
Phosphatidylinositol-specific phospholipase C of Bacillus cereus: cloning, sequence, and 
relationship to other phospholipases. J. Bacteriol. 171: 6077-6083. 
67. Tso, J. Y. and Siebel, C. 1989. Cloning and expression of the phospholipase C gene 
from Clostridium perfringens and Clostridium bifermentans. Infect. Immun. 57. 
468-476. 
68. Titball, R. W, Hunter, S. E. C , Morris, B. C, Schuttleworth, A. D, Rubidge, T., 
Anderson, D. W, and Kelly, D C 1989. Molecular cloning and nucleotide sequence of 
the alpha toxin (phospholipase C) sequence of Clostridium perfringens. Infect. Immun. 
57: 367-376. 
24 
69. Leslie, D, Fairweather, N., Pickard, D , Dougan, G, and Kehoe, M. 1989. 
Phospholipase C and haemolytic activities of Clostridium perfringens alpha toxin cloned 
in Escherichia coli: sequence and homology with a Bacillus cereus phospholipase C. 
Mol. Microbiol. 3: 383-392. 
70. Tsutsui, K., Minami, J., Matsushita, O, Katayama, S., Taniguchi, Y, Nakamura, S., and 
Okabe, A. 1995. Phylogenic analysis of phospholipase C genes from Clostridium 
perfringens types A to E and Clostridium novyi. J. Bacteriol. 177: 7164-7170. 
71. Leimeister-Wachter, M., Domann, E., and Chakraborty, T. 1991. Detection of a gene 
encoding a phosphatidylinositol-specific phospholipase C that is co-ordinately expressed 
with listeriolysin in Listeria monocytogenes. Mol. Microbiol. 5: 361-366. 
72. Vazquez-Boland, J. A., Kocks, C, Dramsi, S., Ohayon, H., Geoffroy, C , Mengaud, J, 
and Cossart, P. 1992. Nucleotide sequence of the lecithinase operon of Listeria 
monocytogenes and possible role of lecithinase in cell-cell spread. Infect. Immun. 
60:219-230. 
73. Daughtery, S. and Low, M. G. 1993. Cloning, expression, and mutagenesis of 
phosphatidylinositol-specific phospholipase C from Staphylococcus aureus: a potential 
staphylococcal virulence factor. Infect. Immun. 61: 5078-5089. 
74. Merino, S., Aguilar, A , Nogueras, M. M., Regue, M , Swift, S., and Tomas, J. M 1999. 
Cloning, sequencing, and role in virulence of two phospholipases (A1 and C) from 
mesophilic Aeromonas sp. serogroup 0:34. Infect. Immun. 67: 4008-4013. 
75. Bailee, B. L. and Auld, D. 1993. New perspective on zinc biochemistry: Cocatalytic 
sites in multi-zinc enzymes. Biochem. 32: 6493-6500. 
25 
76. Berridge, M. J. and Irvine, R F. 1989. Inositol phosphates and cell signaling. Nature. 
341. 197-204. 
77. Titball, R. W., 1997. Clostridial phospholipases. In The Clostridia: Molecular Biology 
and Pathogenesis. Pp. 223-242. University Press, Cambridge. 
78. Titball, R. W, Leslie, D. L, Harvey, S., and Kelly, D. Hemolytic and sphingomyelinase 
activities of Clostridium perfringens alpha-toxin are dependent on a domain homologous 
to that of an enzyme from the human arachidonic acid pathway. Infect. Immun. 59: 
872-1874. 
79. Bryant, A. E, Chen, R. Y. Z, Nagata, Y , Wang, Y., Lee, C H., Finegold, S., Guth, P. 
H., and Stevens, D. L. 2000. Clostridial gas gangrene. I. Cellular and molecular 
mechanisms of microvascular dysfunction induced by exotoxins of Clostridium 
perfringens. J. Infect. Dis. 182: 799-807. 
80. Camilli, A, Goldfine, H, and Portnoy, D. A. 1991. Listeria monocytogenes mutants 
lacking phosphatidylinositol-specific phospholipase C are avirulent. J. Exp. Med. 173: 
751-754. 
81. Chin, J. C. and Watts, J. E. 1988. Biological properties of phospholipase C purified 
from a fleecerot isolate of Pseudomonas aeruginosa. J. Gen. Microbiol. 134: 
2567-2575. 
82. Williamson, E. D. and Titball, R. W. 1992. A genetically engineered vaccine against 
the alpha toxin of Clostridium perfringens protects mice against experimental gas 
gangrene. Vaccine. 11: 1253-1258. 
26 
83. Moolten, F. L , Schreiber, B. M, and Zadjel, S. H. 1982 Antibodies conjugated to 
potent cytotoxins as specific antitumour agents. Immunol. Rev. 62: 47-73. 
84. Chovnich, A, Schneider, W. P, Tso, J. Y., Queen, C , and Chang, C. N. 1991 A 
recombinant membrane acting immunotoxin. Cancer Res. 51: 465-467. 
27 
CHAPTER 3. CLONING AND MOLECULAR CHARACTERIZATION OF THE 
BETA TOXIN (PHOSPHOLIPASE C) GENE OF CLOSTRIDIUM HEMOLYTICUM 
A paper to be submitted to Anaerobe 
Paul J. Hauer, D.V.M., M.S.1 and Ricardo F. Rosenbusch, D.V.M., Ph. D -
Abstract 
The phospholipase C (PLPC) gene from Clostridium hemolyticum was cloned using the 
polymerize chain reaction. Primers were selected from a consensus sequence of closely 
related clostridial PLPC genes and used to amplify an 871-base pair internal segment of the 
gene. The internal sequence was used to design nested primers which, together with 
adapter-specific primers, were used to amplify upstream and downstream sequences. The 
sequences of upstream and downstream segments were aligned with the internal segment to 
obtain the entire gene sequence. Primers were selected from the aligned sequence, and the 
entire gene was amplified and ligated into a plasmid. An open reading frame which encodes a 
399-amino acid protein, containing a 27-amino acid signal sequence, was identified. The 
molecular weight of the active protein was 42,869 deletions. A 16-amino acid N-terminal 
sequence determined by Edman degradation exactly matched the putative amino acid 
sequence of the gene product. Comparison of the nucleotide and amino acid sequences with 
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Genbank databases demonstrated that the beta toxin of C. hemolyticum exhibits high 
homology with other bacterial PLPCs. The N-terminal portion of the beta toxin contains the 
zinc-binding domain common to other bacterial PLPCs, and the C-terminal domain of the beta 
toxin protein shows considerable homology with the C-terminal domains of 
C. perfringens alpha toxin and C. novyi type A PLPC, and the N-terminal domain of bovine 
arachidonate 5-lipoxygenase. 
Introduction 
Clostridium hemolyticum is an anaerobic, spore-forming bacterium capable of producing a 
rapidly fatal disease known as "bacillary hemoglobinuria" or "redwater". Bacillary 
hemoglobinuria is primarily a disease of cattle, although it has also been reported in sheep, 
hogs, horses, buffalo, and elk1~s. Bacillary hemoglobinuria is present in many livestock-
producing countries throughout the world, including the United States, Wales, New Zealand, 
Canada, Australia, Romania, Turkey, Cuba, the West Indies, Mexico, Venezuela, Chile, 
Brazil, Iran, Ireland, and India6"19. The disease manifests itself after some predisposing factor, 
such as the migration of immature liver flukes, damages the liver, and produces a necrotic 
area. Dormant C. hemolyticum spores germinate in the resulting anaerobic environment. 
Bacteria grow and exude toxins, resulting in tissue destruction, clinical disease, and death. 
Typically, the incidence of the disease is <2 % in infected herds, but death losses up to 25% 
have been reported in naive cattle herds moved to infected pastures20. 
Like other species of the genus Clostridia, most, if not all, of the pathogenicity of 
C. hemolyticum is attributed to the production of biologically active exotoxins. The main 
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toxin of C. hemolyticum is a phospholipase C, known as beta toxin. The beta toxin lyses 
hepatocytes and erythrocytes and damages capillary endothelium, which leads to 
hemoglobinuria and loss of vascular fluids into tissues and serous cavities. Death usually 
occurs within 24-36 hours of the onset of clinical disease and is believed to be caused from 
anoxia, resulting from the destruction of erythrocytes21. 
Despite its potentially critical role in disease pathogenesis, relatively little has been done to 
characterize beta toxin. Beta toxin cleaves the phospholipid phosphatidylcholine by hydrolysis 
into phosphocholine and a diglyceride22. It is stable when heated to 50°C for 60 minutes, is 
rapidly inactivated by trypsin, and has a reported molecular weight (MW) of32,000 daltons23. 
Serologically, the beta toxin of C. hemolyticum is identical to the beta toxin of C. novyi type 
B, but distinct from the PLPCs of C. novyi type A, C. perfringens type A, and 
C. bifermentans 24. 
Several bacterial PLPC genes have been cloned and characterized, including those from 
Pseudomonas aeruginosa25, P. cepacia26 , Bacillus thuringiensis27, B. cereus2S, Clostridium 
bifermentans29, C. perfringens3<U1, C. novyi type A32 , Listeria monocytogenesî3-34, 
Staphylococcus aureus™, and Aeromonas hydrophilia36. Molecular characterization of these 
genes and their products have led to key insights into the pathogenesis and control of the 
diseases they produce. The N-terminal 250 amino acids of PLPCs from the gram-positive 
bacteria are highly conserved. All consist of a single polypeptide chain that contains 
essentially placed amino acids necessary for the coordinated binding of zinc ions, which are 
required for enzymatic function37-38. The 3 PLPC genes which have been sequenced from 
clostridial species have nucleotide homologies of approximately 65%. 
In this study, the high degree of homology in the known clostridial PLPC gene sequences 
was utilized to determine the sequence of the beta toxin gene of C. hemolyticum. The purpose 
of the study was to determine the C. hemolyticum beta toxin gene sequence, to compare the 
sequence to other known bacterial PLPC genes, and to use the DNA sequence to predict 
characteristics of the protein. 
Materials and Methods 
Bacterial strains and cultivation. The Clostridium hemolyticum isolate used in this study 
was strain 7170, obtained by the United States Department of Agriculture, Animal and Plant 
Health Inspection Services, National Veterinary Services Laboratories (USDA, APHIS, 
NVSL) in Ames Iowa, from Montana State University, Bozeman, MT. The C. novyi type A 
isolated used in this study was strain 6005, obtained by USDA, APHIS, NVSL from Cutter 
Laboratories, Kansas City, MO. All clostridial organisms were incubated at 37°C in an 
anaerobic system (model 1024, Forma Scientific, Marietta, OH). Cultures for DNA isolation 
and toxin purification were grown in dialysis tubing (12,000-14,000 MW cutoff, Spectrum 
Medical Industries, Los Angeles, CA) suspended in peptic digest. The dialysis tubing was tied 
to hollow glass rods which were inserted through holes in rubber stoppers fitting 1 L blood 
collection tubes containing the peptic digest. The dialysis bags were filled with 100 ml 0.01M 
phosphate buffer, lowered into the peptic digest, and allowed to equilibrate overnight in the 
anaerobic chamber. The dialysis bags were inoculated through the hollow glass rods by the 
addition of 5 ml of an actively growing culture in liver egg brain media. Cultures were grown 
to stationary phase (approximately 16 hours) prior to harvest 
Isolation of DNA. DNA was isolated from C. hemolyticum and C. novyi by the 
lysozyme-sodium dodecyl sulfate-(SDS)- proteinase K method. Cells were harvested from 
the dialysis tubing by centrifugation, re-suspended in 400 ml TEN buffer (lOmM Tris 
hydrochloride [pH 8.0], 3mM EDTA), and centrifuged again. The original supernatant was 
used for toxin purification. The washed cells were re-suspended in 55 ml of TEN buffer 
containing 100^g/ml of lysozyme and incubated with gentle agitation at 37°C for 2 hours. 
Protoplasts were harvested by centrifugation and re-suspended in TEN containing lOO^g/ml 
proteinase K and 0.5% (w/v) SDS. The mixture was incubated overnight in a 50°C water 
bath. The mixture was extracted with phenol-chloroform-isoamyl alcohol (25:24:1) 3 times 
followed by a chloroform-isoamyl alcohol (24:1) extraction. DNA was precipitated with 
ethanol, spooled from the ethanol precipitates, washed with 70% ethanol, and re-suspended in 
TE. DNAase free RNAse was added to concentration of 100 ng per ml and incubated at 
37°C for 1 hour. The mixture was then extracted once with phenol-chloroform-isoamyl 
alcohol and once with chloroform-isoamyl alcohol, ethanol precipitated, and re-suspended in 
TEN 
Polymerase chain reaction (PCR) products were purified by electrophoresis on 1% agarose 
gels containing 0.0005% ethidium bromide and extracted using Quantum Prep® Freeze 'N 
Squeeze DNA gel extraction spin columns (Bio-Rad, Hercules, CA). Gel-purified PCR 
reaction products were ligated into the plasmid pCR ® 2.1 using the TOPO TA® cloning kit 
(pCR2.1 TOPO, Invitrogen, Carlsbad, CA). Plasmid DNA was chemically transformed into 
competent Escherichia coli cells (TOPIOF', Invitrogen, Carlsbad, CA). The transformed 
culures were added to 250^1 of room temperature SOC media* and incubated at 37°C for 1 
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hour with moderate shaking. The cultures were plated on Luria-Bertani (LB) agar plates 
containing ampicillin (50 ug per ml) and isopropylthiogalactoside (IPTG) (20 mM) and grown 
aerobically overnight at 37°C. Several well isolated white colonies from each transformation 
reaction were selected for screening. Individual colonies were used to incubate tubes 
containing 10 ml aliquots of LB media containing ampicillin (50 ug per ml). The cultures 
were incubated aerobically overnight at 37°C with moderate shaking. Plasmid DNA was 
isolated from the individual clones using a Wizard® Plus SV Miniprep kit (Promega, 
Madison, WI). Plasmids were cut with restriction endonuclease EcoR I, and the fragments 
separated by electrophoresis on 1% agarose gels containing 0.0005% ethidium bromide. 
Plasmids containing inserts of the correct size were selected for sequencing. 
PCR reaction and primer selection, and cloning of internal gene sequence. The initial 
PCR reaction was designed to amplify an internal portion of the PLPC sequence. DNA 
sequences for the PLCP genes of C. perfringens, C. bifermentans, and C. novyi type A were 
obtained from the National Center for Biotechnology Information (reference numbers 
AF204209, AF072123, and D32125, respectively). Sequences were aligned, consensus 
sequences were identified, and primers were selected using SeqLab software (Genetics 
Computer Group, Madison, WI). Consensus sequences were defined as those matching at 
least 2 of the 3 aligned PLPC gene sequences. Seven primers were selected in areas of highest 
homology (Figure 1). When there was no consensus sequence because the base differed in all 
three known PLPC sequences, the sequence from the PLPC gene of closely related C. novyi 
type A was used. The primers were used in 6 different pair combinations in 6 PCR reactions. 
All thermocycling reactions were conducted on a GeneAmp® PCR System 2400 (Applied 
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Biosystems, Forest City, CA). The thermocycling parameters for the PCR were: 38 cycles of 
94°C for 15 sec, 46°C for 30 seconds, 72°C for 30 seconds. The PCR reactions were 
conducted at various stringencies using the FailSafe® PCR Premix Selection Kit (Epicentre 
Technologies, Madison, WI). PCR reaction products using C. hemolyticum template DNA 
were compared to a products from a control reaction using C. novyi type A DNA template. 
Bands of equal size were extracted from the gel, ligated with plasmid DNA, chemically 
transformed into competent Escherichia coli cells (TOPIOF, Invitrogen, Carlsbad, CA), 
expanded, and purified for sequencing. 
Primer A: 5' - GGGATGGTAAAAAAGATGGAAC - 3' 
Primer B: 5' - CATGGGATGGTAAAAAAGATGG - 3' 
Primer C 5' - AGATGGAACAGGAACTCATTC - 3' 
Primer D: 5' - ATGATTTTCAGCTAGGGTCTAC - 3' 
Primer E: 5' - CATTTGCAGCATGATATGGAG - 3' 
Primer F: 5' - CTCTTGCTGAATAATCCCAATC - 3' 
Primer G: 5' - CTGGATTGTCTAATGTCCATTC - 3' 
Primer combinations for PCR: A&F, B&E, C&E, C&G, D&E, D&F 
Figure 1. Consensus primer sequences and primer combinations used in PCR to obtain 
internal gene segment of C. hemolyticum PLPC gene. 
Obtaining upstream and downstream sequences. Once an internal segment was 
sequenced, upstream and downstream segments of the C. hemolyticum PLPC gene were 
amplified using the Universal Genome Walker® Kit (Clonetech Laboratories, Palo Alto, CA). 
Clostridium hemolyticum genomic DNA was digested in 5 separate reactions with 5 
blunt-end cutting endonucleases (2.5 ug DNA and 1 endonuclease per reaction): Pvu 0, Stu 
I, Sea I, EcoR V, and Dra I. The cut DNA was extracted once with phenol-chloroform-
isoamyl alcohol, once with phenol-isoamyl alcohol, then ethanol precipitated, and 
re-suspended in TEN buffer. Genome Walker® DNA adapters were ligated to the digested 
DNA. Nested upstream and downstream primers, which were compatible with nested 
adapter-specific primers provided with the kit, were designed from the internal sequence 
obtained in the initial PCR reaction (Figure 2). The first upstream and downstream PCR 
reactions were performed using the Universal Genome Walker kit reagents with the outer 
primers. The thermocycler program was: 7 cycles of 94°C for 2 seconds, 70°C for 3 minutes 
followed by 32 cycles of 94°C for 2 seconds, 65°C for 3 minutes, and a single cycle of 70°C 
for 4 minutes. Reactions with visible products in an agarose gel were used as template in the 
second nested PCR reaction using the inner primers. DNA bands on agarose gels from the 
second nested upstream and downstream PCR reactions were extracted, ligated into plasmids, 
and expanded for sequencing. 
Obtaining the complete gene sequence. Overlapping sequences between the inner gene 
segment and the upstream and downstream segments were aligned to generate a complete 
putative sequence. Primers flanking the putative gene were designed from upstream and 
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downstream sequences, and PCR was performed. A 1571 base pair amplification product 
was extracted and ligated into a plasmid for sequencing. 
a) 
5' - GTAATACGACTCACTATAGGGCACGCGTGGTCGACGGCCCGGGCTGGT - 3* 
I I I I I I I I I I 
I I 3* - H2N-CCCGACCA-P04 - 5* 
b) 
Outer adapter primer: 5' - GTAATACGACTCACTATAGGGC - 3' 
Inner adapter primer: 5' - ACTATAGGGCACGCGTGGT - 3' 
Outer upstream primer. 5' - ACAATGTTCAAATAGGTAGCGGTGGAA - 3' 
Inner upstream primer: 5' - CATTTCGGAATTGAAGCAAAAGATGGA - 3' 
Outer downstream primer: 5' - CATTTTTCAGTATCTCTACGGCTTGTG - 3' 
Inner downstream primer: 5' - CGGCTTGTGTAACTATTAATGAATGAG - 3' 
Figure 2: a) Nucleotide sequence of adapter which was ligated C. hemolyticum DNA . b) 
Primer sequences for nested PCR reactions used to obtain upstream and downstream 
sequences. 
Toxin purification for N-terminal protein sequencing. Protease inhibitor cocktail 
(Product # P 8465, Sigma, St. Louis, MO) was added to culture supernatant (1% v/v) and the 
solution was cooled to 4°C. Proteins were precipitated with saturated (NH4)2S04 (40% v/v) 
and removed by centrifugation at 15,000 x g for 30 minutes. The precipitate was discarded. 
Additonal (NHO2SO4 was added to the supernatant to bring the final concentration to 55% 
(v/v). Newly precipitated proteins were harvested from the culture supernatant by 
centrifugation, resolubilized in 1/10 volume sterile water, and dialyzed against deionized 
water. 
The harvested toxin was further purified by preparative isoeclectric focusing and tested for 
PLPC activity. Two ml of carrier ampholyte, pH gradient 3-10 (Biolyte 3/10, Bio-Rad 
Laboratories, Hercules, CA) was added to 50 ml of protein solution. The solution was placed 
in a preparative isoelectric focusing chamber (Rotofor® IEF,Bio-Rad Laboratories, Hercules, 
CA) for 2.5 hours at 12 watts. Twenty fractions from the preparative isoelectric focusing 
chamber were harvested, and the pH of each was recorded. Each fraction was adjusted to pH 
7.0 using either NaOH or HC1. A 20 fil aliquot of each fraction was dropped into wells cut in 
egg yolk agar plates and incubated for 12 hours at 37°C. The zone of color change around 
the wells, indicating phospholipase activity, was measured. Lethal activity of the fractions 
was determined by injecting 0.2 ml of a 1:2 dilution of each fraction intravenously into 2 mice. 
The proteins in fractions demonstrating PLPC and lethal activity were separated by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis, blotted to PVDF membranes, and stained 
with a Comassie blue stain to ascertain the protein content and purity A protein band that 
quantitatively correlated with PLPC activity was cut from the PVDF membrane and used for 
N-terminal sequencing. 
Nucleotide and N-terminal protein sequencing. DNA sequencing was conducted at the 
Iowa State University DNA facility using a model 377 Prism DNA sequencer (Applied 
Biosystems, Inc., Foster City, CA). The internal, upstream, downstream, and complete PCR 
products were all sequenced in both directions using primer walking technique. N-terminal 
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protein sequencing was conducted by the Edman degradation method at the Iowa State 
University Protein facility using a 494 Procise Protein Sequencer/ 140C Analyzer (Applied 
Biosystems, Inc., Foster City, CA). Nucleotide and protein sequences were compared with all 
known sequences in the GenBank data base by using the BLAST program and MacDnasis® 
software (Hitachi Software Engineering America, Ltd., San Bruno, CA). 
Results 
Internal gene sequence. Seven primers were selected and were combined in unique pairs to 
run 6 PCR reactions. A single reaction, using primers C and G (Figure 3), yielded an 
871-base pair PCR product which was similar in size to the product from the C. novyi type A 
C. perfringens AGA TTG AT G GAA GAG GAA CTC 
C. bifermentans AGA TGG AAC AGG GAC ACA TTC 
C. novyi type A AGA TGG TAC AGG AAC TCA TTC 
Consensus (primer 1) AGA TGG AAC AGG AAC TCA TTC 
I I  I I I  I I  I I I  I I I  I I I  I  I  
C. hemolyticum sequence TGA TGG CAC AGG AAC TCA TGC 
C. perfringens GAG TGG ACA AT G GAC AAC CCT G 
C. bifermentans GAA TGG AAA TTA GAT AAT GCA G 
C. novyi type A GAA TGG ACA TTA GAC AAT CCA G 
Consensus (primer 2*) GAA TGG ACA TTA GAC AAT CCA G 
I I I  I I I  I I  I  I I I  I I  I I I  I  
C. hemolyticum GAA TGG ACT CTT GAC ATA CCA G 
Figure 3. Aligned gene sequences used for successful primer selection to amplify an internal 
871-base pair sequence of the C. hemolyticum PLPC gene. *Primer sequence was from 
complementary strand. 
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utm <m «*-
1 2  3  
Figure 4: PCR products from reaction using primers C and G. Lane 1 : C. hemolyticum 
template with 3 mM MgCl, Lane 2: C. hemolyticum template with 5 mM MgCl, Lane 3 : 
C. novyi type A template with 5 mM MgCl 
control reaction (Figure 4). The nucleotide sequence of the PCR product had areas of high 
homology with the PLPC genes from C. novyi type A, C. perfringens, and C. bifermentans. 
Upstream and downstream sequences. The first of 2 nested PCR reactions utilizing the 
outer primers for upstream reaction resulted in a single band using DNA digested with Pvu II 
as a template, and multiple faint bands using the Stu I, Sea I, and EcoR V digested DNA 
templates. The first of the 2 nested PCR reactions utilizing the outer primers for the 
downstream reaction resulted in multiple faint bands using the Pvu II and EcoR V digested 
template (Figure 5a). The second nested PCR reactions using the inner primers and template 
from positive samples in the first PCR reaction resulted in single, well defined bands in one 
downstream reaction (Pvu I digest), and one upstream reaction (EcoR V digest) (Figure 5b). 
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a) b) 
1  2  3  4  5 6 7  8 9  1 0  1 1  1 2  1 2  3  4  5 6  7  8 9  1 0  
Figure 5. a) Results from initial PCR reactions with outer upstream primers (lanes 2-6) and 
downstream primers (lanes 7-11) using adapter ligated-genomic DNA cut with 5 different 
endonucleases as template. Lane 1: molecular size markers, Lanes 2 and 7: Pvu n, Lanes 3 
and 8: S tu I, Lanes 4 and 9: Sea I, Lanes 5 and 10: EcoR V, Lanes 6 and 11 : Dra I., Lane 
12: positive control, b) Results from secondary PCR reactions using inner upstream primers 
(lanes 2-5), and inner downstream primers (lanes 6 and 7) and PCR products from the initial 
PCR reaction as template. Lanes 1 and 10: molecular size markers. Lanes 2 and 6: Pvu n, 
Lane 3: StuI, Lane 4: Sea I, Lane 5 and 7: EcoR V, Lane 8 : negative control, Lane 9: 
positive control. 
Protein: Phospholipase and lethal activities were present in isoelectric focused fractions with 
isoelectric points between 6.9 and 7.5. The activities were further correlated to a protein band 
on the stained PVDF membranes of approximately 43,000 daltons with an isoelectric point of 
approximately 7.2. The sequence of 16 N-terminal amino acid residues from this purified 
protein were in complete agreement with amino acids 29-44 of the predicted amino acid 
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sequence derived from the C. hemolyticum gene sequence. These results suggest that the 
C. hemolyticum PLPC gene product has a 27 N-terminal amino acid signal sequence typical of 
those found in the other 3 clostridial PLPCs (Figure 6). 
a. 7DGKVDGTGTHALIVTQ 
b. MNKKKILKFICSAVLSFTLFSGYKSYA WDGKVDGTGTHALIVTQ 
c. MKRKIYKLLI CAT IATS LWAVRTTKVYA WDGKADGTGTHAMIATG 
d. MKKKFLKGLCCAFVISITCLGASSKAYG WDGKKDGTGTHSMIVTQ 
e. MKALKKVSNILCVLGLCTLMGGTSYA WDGKKDGTGTHSLIAEH 
Figure 6. a. The amino acid sequence obtained by N-terminal sequencing of C. hemolyticum 
beta toxin, b. The predicted N-terminal amino acid sequence obtained from nucleotide 
sequence, c. The predicted amino acid sequence of C. perfringens alpha toxin obtained from 
nucleotide sequence, d. The predicted amino acid sequence of C. novyi type A PLPC 
obtained from nucleotide sequence, e. The predicted amino acid sequence of 
C. bifermentans PLPC obtained from nucleotide sequence. Known signal sequences are 
underlined. 
Complete gene sequence. The complete nucleotide sequence of the C. hemolyticum PLPC 
gene is shown in Figure 7. The coding sequence consists of493 (41%) adenine residues, 369 
(28%) thymidine residues, 150 (13%) cytosine residues, and 219 (18%) guanidine residues. 
A single open reading frame extends from base pairs 322 -1521, which would encode a 
399-amino acid protein with a predicted molecular weight of45,940 da The predicted 
molecular weight of the active toxin without the 27 amino acid signal sequence is 42,869 da. 
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Figure 7 
1 CCTTGTTATT GTTATTGTGT GAGAGCTTAA TTATAACAGG ATTTTGTATA 
51 AATGTTTTTT TGTTTTATTT AACTGTAAAA TTATTCAATC ATTTTTGCAC 
101 CATTATAGTT AATAATATAT TTAATTAAAT ATTAAAAATA ATTACTATAT 
151 ATAGAAAAAA CAAATTTAGG TGTAAAGTAA TAAAAAAAAA GCACGAAAAT 
2 0 1  A T T A A T A A T A  T A T  T A A T  A A A  AAGATGGGAA TATATGATTA ATTTAAATGA 
( - 3 5 )  
2 5 1  T A C T A T A A A A  A A T  A T  T A A A A  A T G G T A T T T T  A A A A T  T  C A T  C  A T T T T C A T C T  
(-10) 
3 0 1  A A A T A A A A G G  A G G A A C A T A T  T  
( S .  D . )  
3 2 2  A T  G  A A T  A A G  A A A  A A A  A T A  T T A  A A A  T T T  A T T  T G T  A G C  G C A  G T A  
( l ) M N K K K I  L K F I C S A V  
U 
3 6 4  T T A  T C A  T T T  A C A  T T A  T T T  T C A  G G C  T A T  A A A  A G T  T A C  G C A  T G G  
( 1 5 )  L  S  F T L F S G Y K S Y A  * W "  
4 0 6  G A T  G G A  A A A  G T T  G A T  G G C  A C A  G G A  A C T  C A T  G C A  T T A  A T A  G T T  
(29) D G K V D G T G T *Jf A L I V 
4 4 8  A C A  C A A  G C T  G T A  G A G  A T A  C T G  A A A  A A T  G A T  G T T  A T C  A G T  A C A  
( 4 3 )  T Q A V E I  L K N D V I S T  
4 9 0  T C A  C C T  T T A  A G T  G T A  A A G  G A G  A A T  T T T  A A A  A T T  T T A  G A A  T C T  
( 5 7 )  S P L S V K E N F K I L E S  
5 3 2  A A T  C T C  A A G  A A G  T T A  C A A  C G T  G G T  T C T  A C T  T A T  C C A  G A C  T A T  
(71) N L K K L Q R G S T Y P *D* Y 
5 7 4  G A T  C C A  A A G  G C A  T A T  G C A  T T A  T A T  C A A  G A T  C A T  T T T  T G G  G A T  
( 8 5 )  D  P  K  A  Y  A  L  Y  Q  D  F  W  D  
6 1 6  C C T  G A C  A C A  G A T  A A T  A A T  
( 9 9 )  P  D  T  D  N  N  
6 5 8  T T A  G C A  T A T  G G A  A T C  A A T  
( 1 1 3 )  L  A  Y  G  I  N  
7 0 0  A A G  T T G  T T T  G C A  T T A  G C T  
( 1 2 7 )  K L  F  A  L  A  
TTC ACT AAA GAC AGC AAA TGG TAT 
F T K D S K W Y  
GAA ACA GGA GAA TCT CAG CTA AGA 
E T G E S Q L R  
GAT GAG TGG AAA AAA GGA AAT 
D E W K K G N 
AAA 
K 
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7 4 2  
( 1 4 1 )  
TAT 
Y 
GAA 
E 
CAA 
Q 
GCA 
A 
7 8 4  
( 1 5 5 )  
TTT 
F 
GGG 
G 
GAC 
D 
TTC 
F 
8 2 6  
( 1 6 9 )  
GCT 
A 
GTA 
V 
GAT 
D 
AGT 
S 
8 6 8  
( 1 8 3 )  
GAA 
E 
GGA 
G 
AAA 
K 
AAA 
K 
910 
( 1 9 7 )  
AAT 
N 
AGT 
S 
GTA 
V 
AAG 
K 
952 
( 2 1 1 )  
AAT 
N 
CTT 
L 
GAT 
D 
AAT 
N 
9 9 4  
( 2 2 5 )  
AAG 
K 
AAG 
K 
GCT 
A 
AAA 
K 
1 0 3 6  
( 2 3 9 )  
CAT 
H 
AGT 
S 
TGG 
W 
AAA 
K 
1 0 7 8  
( 2 5 3 )  
CAC 
H 
AAT 
N 
GTT 
V 
CAA 
Q 
1120 
( 2 6 7 )  
C T T  
L 
AAT 
N 
GAA 
E 
GTA 
V 
1162 
( 2 8 1 )  
AAA 
K 
ATA 
I 
AAT 
N 
GAA 
E 
1 2 0 4  
( 2 9 5 )  
GAT 
D 
AAA 
K 
GCA 
A 
GGT 
G 
1 2 4 6  
( 3 0 9 )  
GCA 
A 
AAA 
K 
GAT 
D 
GGA 
G 
1 2 8 8  
( 3 2 3 )  
GGT 
G 
AAT 
N 
GAT 
D 
T T T  
F 
1 3 3 0  
( 3 3 7 )  
AAT 
N 
TTA 
L 
AAA 
K 
GAT 
D 
Figure 7 (continued) 
ACA TGG CTT TTA GGA 
T W L L G 
CAT ACT CCT TAT CAC 
H T P Y H 
GCA GGA CAT ACA AAA 
A G T K 
GAT TCA TAT AAA TTA 
D S Y K L 
GAA TTT TAT CCA ACT 
E F Y P T 
TGG ATA ACA GAA TAT 
W I T E Y 
AAT AT G TAT TAT GCT 
N M Y Y A 
GAC TGG GAA ATA GCA 
D W E I A 
ATA GGT AGC GCT GGA 
I G S A G 
TCA GGA ACA ATC AAT 
S G T I N 
ATA AT G G TA GTA ATA 
I M V V I 
ACA GAC CAT TAT ATA 
T D H Y I 
AAG AAA TAT GAA TGG 
K K Y E W 
GAA AAA AAT CAA GAA 
E K N Q E 
AAT AAG TTA ACA CTT 
N K L T L 
CAA GGC TTA CAT TAC 
Q G L *H* Y 
CCA TCA AAT GTT ACT 
P S N V T 
T T T  G A A  A C T  T A T  G T T  
F *B* T Y V 
CAT ACA GCA GGA GCT 
H T A G A 
ACA TTA CAA AAT ACT 
T L Q N T 
TCT AGA GGT TGG GCT 
S R G W A 
CAT GCT ACT AT G AGT 
H A T M S 
GCT ACT GAG ACT AT G 
A T E T M 
ATA ATA TAC AGA TTC 
I I Y R F 
ACA ACT GAA AAT TCT 
T T E N S 
AAA ACT GCT AAT GAA 
K T A N E 
CAT TTC GGA ATT GAA 
H F G I E 
ACT CTT GAC AAT CCA 
T L D N P 
GAT AGT TAT AGA ATT 
D S Y R I 
CAA GAT ATA GCT AAA 
Q D I A K 
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Figure 7 (continued) 
1 3 7 2  A C A  T G G  A T A  A G A  A A A  G A A  A G A  G G C  G C T  G G A  G T T  C G C  G A T  G A T  
( 3 5 1 )  T W I  R K E R G A G V R D D  
1 4 1 4  T G G  A A A  C C T  G A A  T A T  G T A  A A A  G T A  A T T  A T A  A A T  T C A  G A T  G T T  
( 3 6 5 )  W K P E Y V K V I I N S D V  
1 4 5 6  A A G  T A T  C A A  G C T  A A T  A T T  A A T  G A G  T G G  T T T  G G A  G A T  A A T  A A A  
( 3 7 9 )  K Y Q A N I N E W F G D N K  
1 4 9 8  A C A  T T C  T A T  A T A  A A T  A A T  A A A  T A A  
( 3 9 3 )  T  F  Y  I  N  N  K  S t o p  
1 5 2 2  A A A T T A A A T A  A A A A T T A A G T  A A A A A T T A A G  T A A A A A T T A A  A A A T A A G A G C  
1572 AT GAGTAAAT CTCATGTTTT TATCTTTTTT TAT T GGGAAA ACTAGTAGAG 
1622 AAGATTCTTT AAATTAGATT TAT T TAT TAT ATAAAGAAAG GAGGAATTTT 
1 6 7 2  A T G A G T A A G A  A A A A T A A T A A  A G G A A G A A T C  T T T G G T A C A T  T A C A G  1 7 1 6  
Figure 7: Nucleotide and amino acid sequences of C. hemolyticum beta toxin. Possible 
Shine-Dalgarno (S.D.), -10, and -35 recognition sequences are indicated in bold. The 
experimentally determined amino acid sequence of the N terminus of the mature beta toxin is 
shown in italics. The putative signal sequence cleavage site is marked with U. Amino acids 
thought to be involved in zinc binding, which are highly conserved in bacterial PLPCs, are 
indicated by * *. 
which closely matches the experimentally predicted value of43,000 da., but is significantly 
higher than the reported molecular weight of32,000 da.. The open reading frame was 
preceded by a putative Shine Dalgamo sequence, as well as possible -10, and -35 recognition 
sequences, and terminated by a TAA stop codon. The nucleotide sequence of the PLPC of 
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C. hemolyticum fits the model of the highly conserved domains of other bacterial PLPCs. The 
gene contains the conserved zinc-dependent PLPC domain homologous to those of Listeria 
monocytogenes, Bacillus cereus, C. perfringens, and C. novyi type A. Maximum matching 
comparison using Needleman-Wunsch algorithm (MacDnasis®) indicated highest homology 
with other clostridial PLCPs. The gene was 70% homologous with G novyi type A PLPC, 
70% with C. perfringens alpha toxin, and 68% with G bifermentans PLPC. The predicted 
N-terminal amino acid sequence contained a conserved domain typical of bacterial PLPCs 
including nine residues that have been identified as essential for the binding of three zinc ions 
that are involved with enzymatic function. 
The predicted protein sequence demonstrated 57% homology to C. novyi A PLPC, 54% 
with C. perfringens alpha toxin, and 50% with C. bifermentans PLPC. The C-terminal 160 
amino acids of the gene product demonstrated 34% homology with the N-terminal domain of 
bovine arachidonate 5-lipoxygenase and 32% homology with the corresponding human 
enzyme (Figure 8). 
Discussion: 
Most of the early investigations on bacterial PLPCs focused on their ability to directly 
damage cell membranes as the mechanism involved in producing disease. However, more 
recent studies have focused on subtle and indirect mechanisms by which bacterial PLPCs 
contribute to disease. Bacterial PLPCs can increase intracellular diacylyglycerol and ceramide 
in eukaryotic organisms by cleaving membrane phosophatidylcholine and sphingomyelin, 
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a. 
C. hem WIKTANEDKAGTDHYIHFGIEAKDGKKYEWTLDNP-GNDFEKNQEDSYR 
V + T ++ AGTD YI+ + G + LD P NDFE+ DSY 
bv a51 VTVATGSQWFAGTDDYIYLSLVGSAGCSEKHLLDKP FYNDFERGAVDS YD 
C. hem INLKDNKLTLQDIAKTWIRKERGAGVRDDWKPEYVKV 
+ + + LDI I K R DDW +Y+ V 
bv a51 VTVDEE LGDIQLIKIEK-RKYWFHDDWYLKYITV 
b. 
C. hem WIKTANEDKAGTDHYIHFGIEAKDGKKYEWTLDNP-GNDFEKNQEDSY 
V + T ++ AGTD YI+ + G + LD P NDFE+ DSY 
hu a51 VTVATGSQWFAGTDDYIYLSLVGSAGCSEKHLLDKP FYNDFERGAVDS Y 
C. hem RINLKDNKLTLQDIAKTWIRKERGAGVRDDWKPEYVKV 
+  +  +  L + I  I  K  R  +  D D W  + Y +  
hu a51 DVTVDEE LGEIQLVRIEK-RKYWLNDDWYLKYIEF 
Figure 8: Amino acid homology between a) the C-terminal portion of C. hemolyticum beta 
toxin (amino acids 287-372) and a) the N-terminal segment of bovine arachidonate 
5-lipoxygenase (amino acids 6-88), b) the N-terminal segment of human arachidonate 
5-lipoxygenase (amino acids 6-88). + indicates amino acid substitutions which normally do 
not affect secondary structure. 
activate eukaryotic phospholipases, leading to the formation of inositol 1,4,5 triphosphate and 
inositol 1,3,4,5 tetraphosphate40. Uncontrolled production of these molecules effectively 
deregulates cellular calcium. Bacterial PLPCs also activate the arachidonic acid cascade in 
eukaryotic cells, causing the production of thromboxane and leukotrienes 41 which result in 
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inflammation, edema, platelet aggregation, muscle contraction, and increases in vascular 
permeability. 
Direct destruction of red blood cells has always been thought to be the main factor in the 
pathogenesis of bacillary hemoglobinuria. Although the indirect disease causing mechanisms 
of PLPCs have not been investigated in bacillary hemoglobinuria, the highly conserved PLPC 
domain structure in C. hemolyticum beta toxin indicates that the indirect mechanisms 
demonstrated with other bacterial PLPCs may also contribute to the disease process. 
The most toxic of the PLPCs characterized is the alpha toxin of C. perfringens which 
possesses potent hemolytic, lethal, dermonecrotic, myonecrotic, vascular permeabilizing, and 
platelet-aggregating properties37. Recombinant protein containing the C-terminal domain of 
alpha toxin has been used successfully as a vaccine against gas gangrene42, and the C-terminal 
domain of beta toxin may also be a promising candidate for a recombinant protein vaccine. 
Interestingly, the C-terminal domain of C. hemolyticum demonstrates strong sequence 
homology with the C-terminal domain of alpha toxin which is thought to confer its hemolytic 
and lethal properties. However, the tyrosine 331 and phenylalanine 334 residues in 
C. perfringens alpha toxin which have been identified as essential for cytotoxic activity are not 
conserved in the beta toxin yet it possesses cytotoxic, lethal, and hemolytic activity43. 
Homology between the C-terminal domain of C. hemolyticum beta toxin and the 
N-terminal domain with the bovine arachidonate lipoxygenase enzyme is not surprising 
given that previous studies reported the same homology between the C-terminal domain of 
C. perfringens alpha toxin and the N-terminal domain of human arachidonate 
5-lipoxygenase44. The predicted 3 dimensional protein structure of the C. perfringens alpha 
toxin shows a strong structural analogy to eukaryotic domain which acts as a phospholipid 
and/or calcium binding domain in intracellular second messenger proteins45-46. Similar 
homologies seen between the C. hemolyticum beta toxin, C. perfringens alpha toxin, and 
human and bovine arachidonate 5-lipoxygenase support the likelihood of a similar structure 
for beta toxin. The higher homology between beta toxin and the bovine enzyme may explain 
the higher hemolytic action of beta toxin on bovine red blood cells as compared to human red 
blood cells, and further studies based on this structural similarity are warranted. 
Clinical diagnosis of bacillary hemoglobinuria is normally based on characteristic clinical 
signs and post-mortem findings. Laboratory confirmation of the diagnosis is ideally based on 
cultivation of C. hemolyticum, but the fastidious nature of the organism and contamination by 
other post mortem invading bacteria make the task difficult47. Correct identification of 
C. hemolyticum is complicated by the difficulty in differentiating it from other very closely 
related C. novyi species. Commercially available fluorescent antibody conjugates do not 
differentiate the species, and differentiation is done mainly by demonstrating the presence and 
specific neutralization of 2 toxins, alpha and beta, both of which are lethal when injected into 
mice. Clostridium novyi type A produces alpha toxin, but not beta toxin; C. novyi type B 
produces both toxins; C. novyi type C produces neither toxin; and C. hemolyticum produces 
only beta toxin. In vitro methods used to demonstrate the presence of alpha and beta toxins 
such as cell culture assay, hemolytic activity, or reactivity on egg yolk agar are complicated 
by the presence of non-lethal phospholipases C and lipases produced by C. novyi and 
C. hemolyticum48 and in vivo methods are costly, subject to the availability of reagents, 
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and produce suffering and death in animals. Elucidation of the beta toxin sequence should 
allow development of in vitro methods based on the polymerize chain reaction to aid in 
diagnosis of bacillary hemoglobinuria and differentiation of C. hemolyticum and C. novyi. 
Conclusions: 
The beta toxin gene of C. hemolyticum has been cloned and the nucleotide and putative 
amino acid sequences have been determined. The gene consists of an open reading frame, 
which encodes a 399-amino acid protein containing a 27-amino acid signal sequence. The 
molecular weight of the active protein is 42,869 deletions. The nucleotide and amino acid 
sequences exhibit high homology with other bacterial PLPCs. The N-terminal portion of the 
beta toxin protein contains a zinc-binding domain common to other bacterial PLPCs, and the 
C-terminal domain of the beta toxin protein shows considerable homology with the C-terminal 
domains of C. perfringens alpha toxin and C. novyi type A PLPC and the N-terminal domain 
of bovine arachidonate 5-lipoxygenase. The results of this study along with numerous studies 
on closely related bacterial PLPCs provide the foundation on which to base further research 
aimed at determining the mode of action of beta toxin, as well as improving diagnostic 
techniques and vaccines against bacillary hemoglobinuria. 
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CHAPTER 4. EVIDENCE OF THE PROTECTIVE IMMUNOGENICTTY OF 
CLOSTRIDIUM HEMOLYTICUM PHOSPHOLIPASE C (BETA TOXIN) 
IN GUINEA PIGS 
A paper to be submitted to Vaccine 
Paul J. Hauer, D.V.M., M.S.1 and Ricardo F. Rosenbusch, D V M , Ph D 2 
Abstract: 
The beta toxin of C. hemolyticum was purified by preparative isoelectric focusing and used to 
develop toxin neutralizing and non-neutralizing monoclonal antibodies. Guinea pigs passively 
immunized with toxin-neutralizing monoclonal antibodies were protected from a 100 LDS0 
spore challenge. The toxin-neutralizing ability of the monoclonal antibodies, as measured in in 
vitro and in vivo toxin neutralization assays, correlated to the protective effects in guinea pigs. 
Protection of guinea pigs injected with varying doses of immunoaffinity purified beta toxin 
was correlated to the presence of anti-beta toxin antibodies in the serum. 
Introduction: 
Clostridium hemolyticum is an anaerobic, spore-forming bacterium capable of producing a 
rapidly fatal disease of cattle and sheep known as "bacillary hemoglobinuria" or "redwater". 
The disease was first described by Vawter and Records1 in 1926 as being endemic only in 
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areas of the western United States, but subsequent reports indicate the presence of the disease 
in many livestock producing countries around the world. Like other species of the genus 
Clostridia, most, if not all, of the pathogenicity of C. hemolyticum is attributed to the 
production of biologically active exotoxins. The main toxin of C. hemolyticum is a 
phospholipase C (PLPC), known as beta toxin2. The beta toxin lyses hepatocytes and 
erythrocytes and damages capillary endothelium, which leads to hemoglobinuria and loss of 
vascular fluids into tissues and serous cavities. Death usually occurs within 24-36 hours of the 
onset of clinical disease and is believed to be caused from anoxia, resulting from the 
destruction of erythrocytes3. 
Scientific reports are contradictory as to the relative contributions of C. hemolyticum 
toxoid and cellular components to a protective immune response. Vaccination against 
bacillary hemoglobinuria with inactivated whole culture, as well as with whole culture of live 
avirulent bacteria, was first reported by Vawter and Records in 19294 The protective 
immunity provided by these early vaccines was presumed to be due to beta toxin-neutralizing 
antibodies. Intravenous administration of hyperimmune horse serum containing high levels of 
antitoxin was reported to be an effective treatment if administered early in the course of the 
disease, while administration of a hyperimmune horse serum containing high agglutination 
titers was not, which also suggests the importance of toxoid in inducing protective immunity5. 
However another study established a correlation between agglutination titers and protection 
against a lethal challenge in guinea pigs6; the author of that study concluded that immunity 
was primarily antibacterial in nature. As a result of the contradictory evidence, modern 
textbooks address the topic of immunity to C. hemolyticum with cautious statements, such as: 
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"It has been suggested, but not confirmed that immunity (to bacillary hemoglobinuria) is 
primarily antibacterial,"7 or "The immunity is apparently antibacterial rather than antitoxic in 
nature, although the situation is far from clear"3. 
Currently available commercial vaccines for bacillary hemoglobinuria are 
formalin-inactivated whole cultures or crude culture supernatants that consistently induce 
agglutinating antibodies, but do not consistently induce high levels of antitoxin3. Few, if any, 
major changes in the vaccine formulations have been accomplished, in the seven decades since 
the inception of the prototypes. Vaccination of cattle in endemic areas is commonly practiced, 
though the duration of immunity remains relatively short lived, and revaccination at 6-month 
intervals is normally recommended 9. 
Identification of the specific antigens involved in inducing protective immunity would be a 
key step in developing improved vaccines against bacillary hemoglobinuria. New generation 
vaccines made with purified or recombinant protein may provide longer lasting immunity and 
decrease production costs. The purpose of this study was to determine whether or not the 
beta toxin of C. hemolyticum was a protective immunogen in a guinea pig challenge model. 
Materials and Methods: 
Bacterial strains and cultivation. The Clostridium hemolyticum used in this study was 
strain 7170 obtained by the United States Department of Agriculture, Animal and Plant Health 
Inspection Service, National Veterinary Services Laboratories from Montana State 
University, Bozeman, Montana in 1962. Incubations for clostridial organisms were conducted 
in an anaerobic system. Cultures were grown anaerobically in dialysis tubing (12,000-14,000 
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molecular weight cutoff, Sepctrum Medical Industries, Los Angeles, CA) suspended in peptic 
digest. Cultures were grown to stationary phase (approximately 16 hours) prior to harvest. 
Toxin purification for Mouse Immunization: Protease inhibitor cocktail (Product # P 
8465, Sigma, St. Louis, MO) was added to culture supernatant (1% v/v). Proteins were 
precipitated with saturated (NH*)zS04 (40% v/v) and removed by centrifugation at 15,000 x g 
for 30 minutes; the precipitate was discarded. Additional (NHO2SO4 was added to the 
supernatant to bring the final concentration to 55% (v/v). Newly precipitated proteins were 
harvested from the supernatant by centrifugation, resolubilized in 1/10 volume sterile water, 
and dialyzed against deionized water. 
The harvested toxin was further purified by preparative isoelectric focusing. Carrier 
ampholyte, pH gradient 3-10 (Biolyte 3/10, Bio-Rad Laboratories, Hercules, CA) was added 
(4%v/v). The solution was placed in a preparative isoelectric focusing chamber (Rotofor® 
IEF,Bio-Rad Laboratories, Hercules, CA) for 2.5 hours at 12 watts. Twenty fractions were 
harvested, and the pH of each was recorded. Each fraction was adjusted to pH 7.0. 
Each fraction was tested for phospholipase and lethal activity. A 20-gl aliquot of each 
fraction was dropped into 2 mm diameter wells cut in egg yolk agar plates and incubated for 
12 hours at 37°C. The zone of increased turbidity around the wells, indicating phospholipase 
activity, was measured (Figure 1). Lethal activity of the fractions was determined by injecting 
0.2 ml of a 1:2 dilution of each fraction intravenously into two mice. The proteins in fractions 
demonstrating PLPC and lethal activity were separated by sodium dodecyl sulfate 
polyacrylamide gel electorphoresis, blotted to nitrocellulose membranes, and stained with a 
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Figure 1. Phospholipase C activity, as detected by turbidity in egg yolk agar, of 
C. hemolyticum beta toxin which had been partially purified by preparative isoelectric focusing 
(IEF). The following ŒF fractions are shown: a) pH 6.79, b) pH 7.01, c) pH 7.20, d) pH 
7.52. 
colloidal gold stain (Aurodye Forte, Amersham Pharmacia Biotech, Uppsala, Sweeden). 
Fractions with the fewest visible protein bands were dialyzed overnight against deionized 
water and used to immunize mice for production of monoclonal antibodies. 
Immunization of Mice for Hybridoma Production: Balb/C mice (Harlan Sprague Dawley, 
Indianapolis, IN) were injected four times at 3-week intervals with 0.2 ml of purified toxin. 
The first 2 doses were diluted to contain less than one mouse lethal dose. The third and 
fourth doses contained approximately 5 and 10 mouse lethal doses of toxin, respectively. The 
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first three doses were administered intraperitoneal^, and the final dose was administered 
intravenously. Spleens were harvested for fusion 3 days after the final injection. 
Hybridoma production: Hybridomas were produced using SP2/0 cells (American Type 
Culture Collection, Rockville, MD) according to the method of Van Deusen and Whetstone 10. 
Primary cell culture supernatants were screened by enzyme-linked immunosorbent assay 
(ELISA) using purified C. hemolyticum toxin as the solid phase antigen. Hybridomas 
demonstrating specificity for beta toxin and/or toxin-neutralizing properties were cloned by 
limiting dilution, retested, and selected for further study. 
Toxin neutralization bioassay: A bioassay was used to test the ability of monoclonal 
antibody to neutralize the lethal effects of beta toxin. Beta toxin (50 mouse LDS0 /ml) was 
mixed with an equal volume of monoclonal antibody. The toxin-antibody mixtures were 
incubated at room temperature for 30 minutes prior to injecting 0.2 ml intravenously into each 
of five mice. The mice were observed for 24 or 72 hours, and deaths were recorded. 
Western blots: Western blots were used to confirm the molecular weight of the target 
protein for selected Mabs and to characterize the immune responses of vaccinated guinea pigs. 
Proteins in crude culture supernatant were separated using sodium dodecyl sulfate 
polyacrylamide gel electrophoresis on a 4-20% gradient gels. The separated proteins were 
transferred to nitrocellulose membranes and immunoblotted with murine monoclonal antibody 
or guinea pig antiserum by standard methods. 
Toxin purification using immunoaflinity chromatography: A toxin-neutralizing 
monoclonal antibody made from hybridoma 4C5 was precipitated with equal volumes of 
saturated ammonium sulfate. Approximately 95 mg of the partially purified monoclonal 
61 
antibody was coupled to 10 ml of AminoLink® Coupling gel (Pierce, Rockford, IL ) and 
added to a disposable plastic column (Pierce). Clostridium hemolyticum culture supernatant 
was added to the column and allowed to bind for 30 minutes at room temperature. The 
column was then washed with 100 ml of 100 mM carbonate buffer and eluted with 
ImmunoPure® gentle elution buffer (Pierce). Eluted toxin was dialyzed against 0.155 M 
phosphate-buffered saline for 1 hour at room temperature. After determination of protein 
content (Pierce BCA Protein Assay) and confirmation of PLPC activity, toxin was mixed 
with aluminum hydroxide adjuvant (Rehydragel, Reheis, Berkeley Heights, N.J.)(20%v/v) and 
used to immunize guinea pigs. 
Assay for anti-phosphollpase activity: Monoclonal antibodies that bound to 
C. hemolyticum beta toxin were screened for anti-phospholipase activity on egg yolk agar 
plates Monoclonal antibody was mixed with C. hemolyticum beta toxin (approximately one 
half mouse LD$o) and allowed to incubate at room temperature for 30 minutes. Forty pi of 
toxin-antibody mixture was dropped onto egg yolk agar plates. The plates were incubated at 
37°C and evaluated visually at 4 and 24 hours for zones of increased turbidity, indicating 
toxin-mediated destruction of the cloudy phospholipid in the surrounding agar (Fig. 2). 
Active immunization/challenge of guinea pigs: Eight guinea pigs were injected 
subcutaneously with three, 1 ml doses (approximately 2 ng/ml) of adjuvanted 
C. hemolyticum toxin at 3-week intervals. Two weeks after the final injection, a 5 ml blood 
sample was collected and analyzed by Western blot. The guinea pigs were allowed to recover 
for 24 hours and then injected with 0.5 ml of a standardized C. hemolyticum spore suspension 
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(200 guinea pig LD50/ml) diluted in a 5% CaCb solution. Five non-vaccinated control guinea 
pigs were also challenged. The animals were observed for 72 hours after challenge. 
A second guinea pig challenge test was conducted in the same manner as described above 
with the exception that a total of four guinea pigs were immunized with three, 2-ml doses of 
the purified adjuvanted toxin containing approximately 12 ng/ml of protein. 
Passive immunization/challenge of guinea pigs: Four monoclonal antibodies against 
C. hemolyticum beta toxin were standardized for antibody content. Each monoclonal 
antibody was injected subcutaneously into 2 guinea pigs (2 ml/animal). A control group of 
two guinea pigs was injected with monoclonal antibody against C. perfringens beta toxin. 
Four hours later, the guinea pigs were injected intramuscularly with 100 guinea pig LDSo of 
C. hemolyticum spores in a 5% CaCl2 solution. The animals were observed for 72 hours after 
challenge. 
Results and Discussion: 
Monoclonal antibodies: Four monoclonal antibodies specific for C. hemolyticum beta toxin 
identified as 4C5, 7H11, 9G7, and 11H5, were produced (Table 1). Monoclonal antibodies 
4C5 and 9G7 neutralized beta toxin in all three assays, while 7H11 and 11H5 had no 
neutralizing capacity. Neutralization on the egg yolk agar plates was evident at 4 hours 
post-inoculation (Figure 2). However, by 24 hours post- inoculation, a color change had 
occurred, possibly due to the presence of a lipase which has also been reported to be 
produced by C. hemolyticum2. When immunoaffinity-purified toxin was mixed with 
monoclonal antibody, no color change occurred with 4C5 or 9G7 within a 24 hour period. 
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Table 1. Test results of beta toxin-specific monoclonal antibodies 
Clone # Mouse bioassay 
protected/total 
Effect on PLPC activity 
of toxin 
Western blot Guinea pig challenge 
protected/total 
4C5 4/5' neutralized 43 and 45 kDa 2/22 
7H11 0/5 no effect 45 kDa 0/23 
9G7 5/5 neutralized 45 kDa 2/2 
11H5 0/5 no effect 45 kDa 0/23 
1 2 deaths occurred 48-72 hours post injection. All contro s died within 24 hours post 
injection 
2 Necrotic areas at spore injection site beginning day 2 post injection. 
3 Deaths occurred 24-36 hours post injection. 
Figure 2. Neutralization of PLPC activity of C. hemolyticum beta toxin by monoclonal 
antibodies demonstrated on egg yolk agar, a) 4 hours post inoculation, b) 24 hours post 
inoculation. 
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Recent molecular characterization of the C. hemolyticum gene (submitted for publication) 
indicates that the beta toxin consists of a single protein with a molecular weight of 45,940 
daltons that contains a signal sequence of3071 daltons. These molecular weights compare 
closely to the molecular weights of the bands present in the Western blot in Figure 3. 
1 2 3 4 5 6 
Figure 3. Western blot demonstrating the specificity of monoclonal antibodies against crude 
C. hemolyticum beta toxin. 1) 4C2, 2) 9G7, 3) 7H11, 4) MW markers, 5) 11H5, 6) Control 
monoclonal antibody 
Active immunization/ challenge of guinea pigs: In the initial immunization/challenge test, 3 
of 8 guinea pigs vaccinated with three doses (2 ng/dose) were protected from the 
spore challenge. Western blots from the guinea pigs indicated that protected animals had 
produced beta-toxin specific antibodies, while the unprotected guinea pigs had not ( Figure 4). 
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The repeat immunization/challenge test conducted with a higher immunizing dose resulted in 
100% protection in all vaccinated guinea pigs, and all vaccinated guinea pigs demonstrated 
anti-beta toxin antibodies by Western blot (Figure 5). All control guinea pigs in both tests 
died as a result of challenge. 
Previous studies have indicated that the immunogenicity of beta toxin is destroyed by 
treatment with formalinIU2\ Toxin used to immunize guinea pigs in this study was not 
chemically inactivated and maintained PLPC activity after purification. However, levels of 
toxic activity in the highly purified protein were not high enough to elicit any vaccination site 
reactions or clinical signs in guinea pigs after vaccination. 
A recent surge in the study of bacterial PLPCs has led to the recognition that these 
molecules can be important virulence factors. The PLPCs made by Listeria monocytogenes 
contribute to virulence by facilitating the escape of bacteria from phagolysosomes and the 
double-membraned vesicles formed as a result of cell-to-cell spread of the bacteria. Mutant 
L. monocytogenes deficient in both PLPCs is 500-fold less virulent than the wild type in 
mice 13. Aeromonas hydrophilia mutants lacking PLPC are 10-fold less virulent in fish than 
the same mutants complemented with the PLPC gene w, and the disease in sheep known as 
"fleecerot", caused by Pseudomonas aeruginosa, can be reproduced by intradermal 
inoculation of the purified PLPC l5. 
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a) 1 2 3 4 5 6 7 8 9  1 0  b) 1  2  3 4  5 6  7  
Figure 4. Western blots using serum from guinea pigs vaccinated with C. hemolyticum toxin, 
a) Guinea pigs receiving three doses of approximately 2 pig toxin, a) Lanes 1, 4, and 8: 
guinea pigs which survived challenge. Lanes 2, 3, 5, 6, and 7: guinea pigs which did not 
survive challenge. Lane 9: negative guinea pig serum, Lane 10: monoclonal antibody 4C5 
control, respectively, b) Guinea pigs receiving three doses of approximately 12 ng toxin. 
Lanes 1-4: guinea pigs that survived challenge. Lane 5) negative guinea pig serum, Lane 6) 
MW markers, Lane 7) monoclonal antibody 4C5 control. 
The most toxic of the characterized PLPCs is the alpha toxin of C. perfringens, which is 
closely related to C. hemolyticum beta toxin. Alpha toxin possesses potent hemolytic, lethal, 
dermonecrotic, myonecrotic, vascular permeabilizing, and platelet aggregating properties. 
Interestingly, the C-terminal domain of C. perfringens alpha toxin, which is thought to confer 
its hemolytic and lethal properties, has sequence homology with an enzyme from the human 
arachidonic acid pathway involved in the generation of leukotrienes 16 and represents a 
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prokaryotic analog of a eukaryotic phospholipid and/or calcium-binding C2 domain 17. 
Intradermal administration of alpha toxin in guinea pigs activates lipoxygenase and 
cyclooxygenase pathways, yielding thromboxanes, leukotrienes, and prostaglandins. 
Researchers have recently demonstrated that alpha toxin activates the platelet fibrinogen 
receptor gpHbllla, which results in the binding of free fibrinogen to platelets and formation of 
platelet/granulocyte complexes resulting in sustained thrombosis, vascular injury, and muscle 
destruction18. 
Recombinant vaccine made from the C-terminal portion of alpha toxin is protective in 
mice l9-2°. Results from this study, demonstrating both passive and active immunity against 
C. hemolyticum beta toxin, indicate that C. hemolyticum beta toxin also is a protective 
immunogen. Neutralization of beta toxin may prevent the establishment of the strict anaerobic 
environment required for germination and growth of C. hemolyticum, thereby containing the 
infection and preventing disease. While other antigens from C. hemolyticum may also play a 
role in protective immunity, future efforts to improve the immunity induced against bacillary 
hemoglobinuria that focus on the induction of anti-beta toxin antibodies are warranted. 
Summary: 
Previous studies conducted to identify protective immunogens of C. hemolyticum have been 
inconclusive or contradictory. This study demonstrates that neutralizing monoclonal antibody 
neutralizes toxic, as well as PLPC activities, of beta toxin and passively immunizes guinea pigs 
against a spore challenge. The study also demonstrates the ability of highly purified beta 
toxin to stimulate a protective immune response in guinea pigs. 
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CHAPTERS. GENERAL SUMMARY 
Summary 
Identification and characterization of antigens capable of inducing protective immunity 
are fundamental steps in the improvement of vaccines and methods used to evaluate vaccine 
efficacy. The goals of the research presented in this dissertation were to identify whether or 
not the phospholipase C (beta toxin) of Clostridium hemolyticum was a protective 
immunogen in guinea pigs, and to characterize the beta toxin gene and gene product. 
Guinea pigs immunized with highly purified beta toxin were protected from challenge. 
Guinea pigs passively immunized with beta toxin-neutralizing monoclonal antibodies were also 
protected from challenge. These results establish C. hemolyticum beta toxin as a protective 
immunogen in guinea pigs. 
Beta toxin is a single protein consisting of399 amino acids including a 27-amino acid 
signal sequence. The active toxin has a molecular weight of42,869 and an isoelectric point of 
approximately 7.2. The N-terminal domain of the toxin shares a high degree of homology 
with other bacterial phospholipases C and includes nine highly conserved amino acids thought 
to be involved with coordinated zinc binding. The C-terminal domain of the toxin is highly 
homologous to the closely related PLPCs of C. perfringens and C. novyi and contains a 
domain similar to the eukaryotic C2 domain, which is involved in phospholipid and calcium 
binding. 
A multiplex polymerase chain reaction (PCR) was designed to amplify segments of the 
alpha toxin gene found in C. novyi types A and B and beta toxin gene found in C. novyi type 
72 
B and C. hemolyticum. Preliminary results indicate that the PCR can be used to differentiate 
among C. novyi types A and B and C. hemolyticum, but cannot be used to differentiate 
C. hemolyticum from C. botulinum type C. 
Recommendations for Future Research 
This dissertation provides a strong foundation on which to build future research. One key 
question that still needs to be investigated is whether or not beta toxin can induce protective 
immunity in cattle and sheep. If it can, then the successful expression, purification, and 
possible genetic toxoiding of recombinant beta toxin should be pursued to develop a new 
generation of vaccines against bacillary hemoglobinuria. In addition, a new vaccine potency 
test, based on beta toxoid quantitation or serological measurement of antitoxin induced by 
vaccination, should be developed to replace the current guinea pig challenge test. 
Information from previous studies conducted on C. perfringens PLPC could be used to 
target potentially critical amino acids in C. hemolyticum beta toxin, which are required for the 
toxicity. Point mutation studies conducted on beta toxin, focusing on those critical amino 
acids, would increase our understanding of membrane binding motifs and structure/function 
relationships of PLPCs. 
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APPENDIX A . MULTIPLEX POLYMERASE CHAIN REACTION FOR 
IDENTIFYING ALPHA AND BETA TOXIN GENES IN CLOSTRIDIUM NOVYI 
AND CLOSTRIDIUM HEMOLYTICUM 
A Brief Communication to be submitted to The Journal of Veterinary Diagnostic Investigation 
Paul J Hauer, D.V.M., M.S.1 and Ricardo F. Rosenbusch, D.V.M., Ph. D 2 
Introduction 
Clostridium novyi is a species of anaerobic bacteria capable of producing disease in 
humans and animals. The species is divided into toxigenic types based on production of 2 
major toxins known as alpha and beta1-2 (Table 1). 
Table 1 
C. novyi alpha beta 
Type A + -
Type B + + 
Type C - -
Type D (C. hemolyticum) - + 
Clostridium novyi type A causes wound infections and gas gangrene in humans and animals. 
The main toxin of Clostridium novyi type A is alpha toxin, a protein of approximately 250 
1 Center for Veterinary Biologies, Licensing and Policy Development, United States 
Department of Agriculture, Ames, Iowa 50010 
2 Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa 
State University, Ames, Iowa 50010 
kDa, which causes tissue necrosis and is lethal to mice. Alpha toxin inactivates proteins from 
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the Ho family that regulate actin polymerization in eukaryotic cells3. Clostridium novyi type 
B is an animal pathogen that causes necrotic hepatitis and wound infections. In addition to 
alpha toxin, Clostridium novyi type B produces a hemolytic and lethal phospholipase C known 
as beta toxin. Clostridium novyi type C is non-toxigenic and nonpathogenic. Clostridium 
novyi type D, more commonly known as C. hemolyticum produces beta toxin, but no alpha 
toxin, and is the cause of bacillary hemoglobinuria in animals. 
Differentiation of the types of C. novyi is currently based on demonstration of the toxins in 
serum neutralization tests conducted using cell culture systems, mice, or guinea pigs as an 
indicator of toxic effects2-4. These procedures require the use of standardized reagents, which 
can be difficult to obtain. Some of the tests also require the use of live animals in tests with 
unrelieved pain and suffering, which makes them undesirable, time consuming, and expensive. 
The purpose of this study was to develop a multiplex polymerase chain reaction (PCR) to 
differentiate C. novyi type A, G novyi type B, and C. hemolyticum based on amplification of 
segments of the alpha and beta toxin genes. 
Materials and Methods 
The gene sequences for G novyi alpha toxin (GenBank accessions Z23280 and Z23281 ) 
and G hemolyticum beta toxin (submitted for publication) were searched for optimal PCR 
primer pairs using Oligo 5 (Molecular Biology Insights, Cascade, CO). Primer pairs were 
screened for potential false priming sites and eliminated by checking closely related toxin gene 
sequences including C. difficile toxins A and B (GenBank accession X60984), C. sordellii 
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cytotoxin (GenBank accession X82638), C. perfringens alpha toxin (GenBank accession 
AF204209), C. bifermentans phospholipase C (GenBank accession AF072123), and 
C. novyi type A phospholipase C (Genbank accession D32125). Primers selected for the PCR 
are shown in Table 2. 
Table 2 
Pair No. Alpha toxin primer pairs 
1. 5 ' -AAATTTCTGCGAATAAGTATGC 5 ' -TTTCCCCAATATGTGTGACCAG 1344 bp 
2. 5 '-GGTGGATATTGGGAAAATGACT 5 ' -TTTGGCGTAAGAAACACTCCTG 680 bp 
3. 5 • -TTTAATATTACCATTGGGAGAT 5 ' -TTTTTAGGGGTTGTTTCAAGTA 267 bp 
4. 5 ' - TAG GAGC GACAG CAGTAT CT GA 5 ' -TTTCCCCAATATGTGTGACCAG 305 bp 
Beta toxin primers 
5. 5 • -TTTGTAGCGCAGTATTATCATT 5 '-AGCCTTCTTAGCCCAACCTCTA 494 bp 
6. 5 ' -CTGGGAAATAGCAGCTACTGAG 5 ' -AGCGCCTCTTTCTTTTCTTATC 349 bp 
Product length 
Isolation of DNA. DNA was isolated from C. hemolyticum and C. novyi types A and B by 
the lysozyme-sodium dodecyl sulfate-(SDS)- proteinase K method. Cells were harvested 
from the dialysis tubing by centrifugation, re-suspended in 400 ml TEN buffer (lOmM Tris 
hydrochloride [pH 8.0], 3mM EDTA), and centrifuged again. The original supernatant was 
used for toxin purification. The washed cells were re-suspended in 55 ml of TEN buffer 
containing 100pg/ml of lysozyme and incubated with gentle agitation at 37°C for 2 hours. 
Protoplasts were harvested by centrifugation and re-suspended in TEN containing 1 OO^g/ml 
proteinase K and 0.5% (w/v) SDS. The mixture was incubated overnight in a 50°C 
water bath. The mixture was extracted with phenol-chloroform-isoamyl alcohol (25:24:1) 3 
times followed by a chloroform-isoamyl alcohol (24:1) extraction. DNA was precipitated 
with ethanol, spooled from the ethanol precipitates, washed with 70% ethanol, and 
re-suspended in TEN. DNAase free RNAse was added to concentration of 100 ng per ml and 
incubated at 37°C for 1 hour. The mixture was then extracted once with 
phenol-chloroform-isoamyl alcohol and once with chloroform-isoamyl alcohol, ethanol 
precipitated, and re-suspended in TEN. 
Polymerase Chain Reaction. All thermocycling reactions were conducted on a GeneAmp® 
PCR System 2400 (Applied Biosystems, Forest City, CA). The thermocycling parameters for 
the PCR were: 35 cycles of 94°C for 10 sec, 55°C for 60 seconds, 72°C for 30 seconds. All 
PCR reaction conditions were conducted with 1 primer pair for alpha toxin and 1 primer pair 
for beta toxin using DNA template from a C. novyi type A and B and C. hemolyticum 
reference strains, with a commercial PCR optimization kit (FailSafe PCR Premix Selection 
Kit, Epicentre Technologies, Madison, WI). The reaction volume was 50 nl consisting of 
0.5 nl picomoles of each primer (50 picomoles/|il), 0.5 |il of Taq polymerase (5 units/nl) 
(Boehringer Mannheim, Indianapolis, IN), 1 (il dna template, 21.5 |il water, and 25 p.1 of 
premix. 
Results and Discussion 
The combination of primer pairs 2 and 6, which amplified a 680 base pair segment with 
C. novyi types A and B template and a 349 base pair segment using C. novyi type B and 
C. hemolyticum, respectively, yielded the strongest signal and least background when used in 
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a) b) 
564 
bp 
A B C D E F G H I J K  A B C D E F G H I  J  K  
Figure 1. Optimization of PCR reaction to detect alpha and beta toxins of C. novyi using the 
FailSafe™ PCR Premix Selection kit with primer combination 2 and 6 from table 2. All 
reactions in a) were conducted using C. novyi type A template DNA and all reactions in b) 
were done using C. novyi Type B template. Lane A and K: Molecular size markers Lanes 
B-I: Premixes A-H of kit, Lane J: negative controls. 
a multiplex PCR (Fig. 1). 
Clinical diagnosis of the diseases caused by C. novyi and C. hemolyticum is normally based 
on characteristic clinical signs and post-mortem findings. Laboratory confirmation of the 
diagnosis is ideally based isolation and identification of the etiologic agent, but the fastidious 
nature of these organisms and contamination by other post mortem invading bacteria make the 
task difficult5. Immunohistochemical methods, such as immunofluorescence and 
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—564 bp 
A B C D E F 
Figure 2: PCR typing of C. novyi and C. hemolyticum by amplification of the alpha and beta 
toxin genes. Lanes A: Molecular size markers, Lane B: C. novyi type A, Lane C: C. novyi 
type B, Lane D: C. hemolyticum, Lanes E: C. botulinum strain 468, Lane F: C. botulinum 
strain 202. 
immunoperoxidase staining methods, are used many times in place of culture6. However, 
correct identification of C. novyi and C. hemolyticum is complicated by their close relationship 
within the species as well as with C. botulinum. In fact, C. hemolyticum can be converted to 
C. novyi type B and vice versa by infection with, or curing of, a phage which carries the alpha 
toxin gene1. In addition, C. novyi type A can be converted to C. botulinum type C by 
bacteriophage8. Commercially available fluorescent antibody conjugates do not differentiate 
between types of C. novyi9, and may not be able to differentiate between the closely related 
C. botulinum species. 
This PCR method detects the presence of the alpha and beta toxin genes of C. novyi and 
C. hemolyticum and may be used as an aid in diagnosis of disease. However caution must be 
used when interpreting the results of this test because many animals carry these organisms as 
part of their normal flora10, and multiplication of the organisms post mortem is common. 
Another complicating factor is that C. botulinum type C produces a PLPC which is 
serologically identical to the beta toxin u, and a gene segment of identical size as the C. novyi 
type B/C. hemolyticum PLPC gene segment will amplify in this reaction using C. botulinum 
type C template (Fig 2). Therefore if any suspicion of botulism exists, a PCR reaction 
identifying the type C neurotoxin of C. botulinum type C should be conducted I2. 
Diagnosis of disease caused by C. novyi and C. hemolyticum should include several points of 
consideration in addition to the results of this PCR test including: 1) clinical history, 2) post 
mortem findings, 3) relative numbers of clostridial organisms per microscopic field on stained 
tissue or impression smears, 4) the time that has elapsed between death of the animal and the 
taking of the samples, bearing in mind the ambient temperature 13. 
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*** Prior to publication, this test needs to be evaluated for reproducibility by conducting it 
using template DNA from several well characterized reference strains of C. novyi type A, C. 
novyi type B, and C. hemolyticum. In addition, the reaction needs to be tested for specificity 
using template DNA from C. difficile, C. sordellii, C. perfringens type D, C. bifermentans, 
C. botulinum type C (Stockholm strain), C. chauvoei, and C. septicum. 
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APPENDIX B. AMPLIFICATION OF THE CLOSTRIDIUM HEMOLYTICUM 
BETA TOXIN GENE FOR INSERTION INTO 
AN EXPRESSION PLASMID 
A polymerase chain reaction was designed to amplify the C. hemolyticum beta toxin gene 
for insertion into the expression plasmid pROTet.E133 (Clontech, Palo Alto, CA). Primers 
were designed to incorporate a Hind m restriction endonuclease cut site to facilitate insertion 
into the plasmid's multiple cloning site (Table 1). 
Table 1. PCR primers for insertion into pROTet E133 
Hind in cut site 
Upstream primer 5 ' - GG A4rAGCTT ATGAATAAGAAAAAAATA - 3' 
Downstream primer 5 ' - GG A^AGCTT ATTACTCATCGTCTTA -3' 
PCR reaction. A 50 (j.1 reaction volume made up of 0.5|xl of each primer (50 picomoles/p.1), 
0.5 jil of purified plasmid template (pTOPO containing complete C. hemolytiucm gene 
0.1ngm/nl), 0.5 nl ofTaq polymerase (5 units/fil)(Boehringer Mannheim, Indianapolis, IN), 
23 (il water, and 25 pi of premix B from commercial PCR optimization kit (FailSafe PCR 
Premix Selection Kit, Epicentre Technologies, Madison, WI). The thermocycling reaction 
was conducted on a GeneAmp® PCR System 2400 (Applied Biosystems, Forest City, CA). 
The thermocycling parameters for the PCR were: 35 cycles of 94°C for 10 sec, 65°C for 60 
seconds, 72°C for 60 seconds. 
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Results. A 1265 base pair segment was amplified (Fig. 1). The gene segment was purified by 
gel electrophoresis, cut with Hind II (Roche Chemical, Indianapolis, IN), and ligated into the 
expression vector, which had also been cut with Hind HI. The ligated plasmid was 
introduced into competent Eschericia coli cells by chemical transformation. The culture was 
plated on egg yolk agar supplemented with chloramphenicol and anhydrotetracycline. No 
phospholipase positive colonies were observed. 
Figure 1. Amplification of C. hemolyticum gene for insertion into expression plasmid. Lanes 
A and B: Molecular size markers, Lane C: negative control, Lanes D and E: amplified 
C. hemolyticum gene. 
1500 bp 
1200 bp 
A B C D E 
84 
ACKNOWLEDGMENTS 
I thank Dr. Ricardo Rosenbusch, my major professor, for his expert advice, patience, and 
support. I have gone to him many times to access his vast and diverse collection of 
knowledge and life experiences, and I have always felt comfortable doing so. He is an 
outstanding teacher. I thank also the other members of my graduate committee, Drs. Joseph 
Haynes, James Roth, Louisa Tabatabai, Dan Voytas, and Randall Levings for their time, 
support, and interest in my graduate program. 
I owe a special debt of gratitude to Ms. Mary Sue Whitaker for her outstanding technical 
support. Her enthusiasm for learning new techniques and her meticulous attention to detail 
were invaluable to this project. Special thanks also to Dr. Nancy Clough for her expert 
review of this dissertation. Her tremendous writing skills significantly improved the quality of 
this manuscript. 
Thanks also goes to the administration of the Center for Veterinary Biologies (CVB) for 
allowing me to conduct the research reported in this dissertation as part of my job. The 
opportunity to continue to learn and grow professionally is essential to job satisfaction. I 
hope this research will be helpful to the CVB mission. 
